CN104870017A - 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物 - Google Patents
含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物 Download PDFInfo
- Publication number
- CN104870017A CN104870017A CN201380063816.2A CN201380063816A CN104870017A CN 104870017 A CN104870017 A CN 104870017A CN 201380063816 A CN201380063816 A CN 201380063816A CN 104870017 A CN104870017 A CN 104870017A
- Authority
- CN
- China
- Prior art keywords
- unsubstituted
- base
- amino
- replace
- benzopyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title claims abstract description 85
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title claims abstract description 85
- 230000009977 dual effect Effects 0.000 title claims abstract description 61
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 52
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 claims abstract description 99
- 238000000034 method Methods 0.000 claims abstract description 51
- 108091007960 PI3Ks Proteins 0.000 claims abstract description 48
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 42
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 37
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 34
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 30
- 230000000241 respiratory effect Effects 0.000 claims abstract description 27
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 26
- 208000006673 asthma Diseases 0.000 claims abstract description 22
- 230000001363 autoimmune Effects 0.000 claims abstract description 22
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 15
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims abstract 45
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 137
- -1 appropriate Fei Site Chemical compound 0.000 claims description 71
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims description 71
- 229960002586 roflumilast Drugs 0.000 claims description 71
- 238000011282 treatment Methods 0.000 claims description 64
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 62
- 210000004027 cell Anatomy 0.000 claims description 53
- 201000010099 disease Diseases 0.000 claims description 53
- 150000001875 compounds Chemical class 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 39
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 38
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 21
- 150000002148 esters Chemical class 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- 201000008937 atopic dermatitis Diseases 0.000 claims description 12
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 11
- 201000004624 Dermatitis Diseases 0.000 claims description 11
- 230000036783 anaphylactic response Effects 0.000 claims description 11
- 208000003455 anaphylaxis Diseases 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 9
- 150000001204 N-oxides Chemical class 0.000 claims description 9
- 230000001684 chronic effect Effects 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 239000000651 prodrug Substances 0.000 claims description 9
- 229940002612 prodrug Drugs 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 8
- CVDXFPBVOIERBH-JWQCQUIFSA-N 4-[(4ar,10bs)-9-ethoxy-8-methoxy-2-methyl-3,4,4a,10b-tetrahydro-1h-benzo[c][1,6]naphthyridin-6-yl]-n,n-di(propan-2-yl)benzamide Chemical compound N([C@@H]1CCN(C)C[C@@H]1C=1C=C(C(=CC=11)OC)OCC)=C1C1=CC=C(C(=O)N(C(C)C)C(C)C)C=C1 CVDXFPBVOIERBH-JWQCQUIFSA-N 0.000 claims description 7
- 208000001132 Osteoporosis Diseases 0.000 claims description 7
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 7
- 201000010105 allergic rhinitis Diseases 0.000 claims description 7
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 7
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 7
- 229960003445 idelalisib Drugs 0.000 claims description 7
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims description 7
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 7
- 229960000278 theophylline Drugs 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- 206010010741 Conjunctivitis Diseases 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims description 6
- 229960003556 aminophylline Drugs 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 210000001185 bone marrow Anatomy 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- KYFWUBJMTHVBIF-QFIPXVFZSA-N dsstox_cid_27248 Chemical compound N([C@@H]1N=C(C=2C=3N(C1=O)CCC=3C=C(C=2)C)C=1C=CC=CC=1)C(=O)C1=CC=NC=C1 KYFWUBJMTHVBIF-QFIPXVFZSA-N 0.000 claims description 6
- 206010025135 lupus erythematosus Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- FSDOTMQXIKBFKJ-UHFFFAOYSA-N n-(2,5-dichloropyridin-3-yl)-8-methoxyquinoline-5-carboxamide Chemical compound C12=CC=CN=C2C(OC)=CC=C1C(=O)NC1=CC(Cl)=CN=C1Cl FSDOTMQXIKBFKJ-UHFFFAOYSA-N 0.000 claims description 6
- 208000037916 non-allergic rhinitis Diseases 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 229940100256 oxtriphylline Drugs 0.000 claims description 6
- RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 3H-quinazolinyl-4-one Natural products C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 claims description 5
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 5
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 5
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 5
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 5
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 5
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 5
- 201000002481 Myositis Diseases 0.000 claims description 5
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 5
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 5
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 5
- 206010039710 Scleroderma Diseases 0.000 claims description 5
- 206010052779 Transplant rejections Diseases 0.000 claims description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 5
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 206010046914 Vaginal infection Diseases 0.000 claims description 5
- 201000008100 Vaginitis Diseases 0.000 claims description 5
- 206010047115 Vasculitis Diseases 0.000 claims description 5
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 5
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 claims description 5
- 201000001981 dermatomyositis Diseases 0.000 claims description 5
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- 206010028417 myasthenia gravis Diseases 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 230000000306 recurrent effect Effects 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 206010043778 thyroiditis Diseases 0.000 claims description 5
- 238000002689 xenotransplantation Methods 0.000 claims description 5
- DHCOPPHTVOXDKU-UHFFFAOYSA-N Tofimilast Chemical compound C1CN2C(C=3SC=CC=3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 DHCOPPHTVOXDKU-UHFFFAOYSA-N 0.000 claims description 4
- GVTLDPJNRVMCAL-UHFFFAOYSA-N arofylline Chemical compound C1=2N=CNC=2C(=O)N(CCC)C(=O)N1C1=CC=C(Cl)C=C1 GVTLDPJNRVMCAL-UHFFFAOYSA-N 0.000 claims description 4
- 229950009746 arofylline Drugs 0.000 claims description 4
- 229950001653 cilomilast Drugs 0.000 claims description 4
- QVDKSPUZWYTNQA-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=NC=N[C]21 QVDKSPUZWYTNQA-UHFFFAOYSA-N 0.000 claims description 4
- 229950000579 enprofylline Drugs 0.000 claims description 4
- 229950010090 pumafentrine Drugs 0.000 claims description 4
- XTNYQMSCYWBFJX-KRWDZBQOSA-N (4r)-1-[(4-bromophenyl)methyl]-4-(2-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one Chemical compound C([C@H](CC1=O)C2=CC=C(C=C2OC2CCCC2)OC)N1CC1=CC=C(Br)C=C1 XTNYQMSCYWBFJX-KRWDZBQOSA-N 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
- DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 claims description 3
- UTUUPXBCDMQYRR-HSZRJFAPSA-N 4-[(2r)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine Chemical compound COC1=CC=C([C@H](CC=2C=CN=CC=2)C=2C=CC=CC=2)C=C1OC1CCCC1 UTUUPXBCDMQYRR-HSZRJFAPSA-N 0.000 claims description 3
- QMYRXIWINUJUNY-UHFFFAOYSA-N 4-[6,7-diethoxy-2,3-bis(hydroxymethyl)naphthalen-1-yl]-1-(2-methoxyethyl)pyridin-2-one Chemical compound C=12C=C(OCC)C(OCC)=CC2=CC(CO)=C(CO)C=1C=1C=CN(CCOC)C(=O)C=1 QMYRXIWINUJUNY-UHFFFAOYSA-N 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- RUOGJYKOQBFJIG-UHFFFAOYSA-N SCH-351591 Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)NC1=C(Cl)C=[N+]([O-])C=C1Cl RUOGJYKOQBFJIG-UHFFFAOYSA-N 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 150000003851 azoles Chemical class 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000002357 guanidines Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- NPGREARFJMFTDF-UHFFFAOYSA-N n-(3,5-dichloro-1-hydroxypyridin-4-ylidene)-8-methoxy-2-(trifluoromethyl)quinoline-5-carboxamide Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)N=C1C(Cl)=CN(O)C=C1Cl NPGREARFJMFTDF-UHFFFAOYSA-N 0.000 claims description 3
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical group NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000003149 assay kit Methods 0.000 claims 5
- 206010018498 Goitre Diseases 0.000 claims 3
- 229940124780 PI3K delta inhibitor Drugs 0.000 abstract 1
- 239000002585 base Substances 0.000 description 439
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 114
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 113
- 210000000440 neutrophil Anatomy 0.000 description 38
- 102100040247 Tumor necrosis factor Human genes 0.000 description 35
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 31
- 241001465754 Metazoa Species 0.000 description 30
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 28
- 230000008595 infiltration Effects 0.000 description 22
- 238000001764 infiltration Methods 0.000 description 22
- 239000002158 endotoxin Substances 0.000 description 21
- 229920006008 lipopolysaccharide Polymers 0.000 description 21
- 210000002540 macrophage Anatomy 0.000 description 21
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 230000002401 inhibitory effect Effects 0.000 description 19
- 230000006698 induction Effects 0.000 description 18
- 235000019504 cigarettes Nutrition 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 13
- 230000001629 suppression Effects 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 239000000779 smoke Substances 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 239000012887 cigarette smoke extract Substances 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 238000008157 ELISA kit Methods 0.000 description 8
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 8
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 206010006451 bronchitis Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000028709 inflammatory response Effects 0.000 description 7
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 108010062580 Concanavalin A Proteins 0.000 description 4
- 108010044467 Isoenzymes Proteins 0.000 description 4
- 239000012828 PI3K inhibitor Substances 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000003979 eosinophil Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000012447 hatching Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 229940047889 isobutyramide Drugs 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010028275 Leukocyte Elastase Proteins 0.000 description 3
- 102000016799 Leukocyte elastase Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000038030 PI3Ks Human genes 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000001949 anaesthesia Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012192 staining solution Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 208000037816 tissue injury Diseases 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- GUJVVYUMNWOSAM-UHFFFAOYSA-N 2-(morpholin-4-ylmethyl)-3-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(C=2C=CC=CC=2)=C1CN1CCOCC1 GUJVVYUMNWOSAM-UHFFFAOYSA-N 0.000 description 2
- JBMBVWROWJGFMG-UHFFFAOYSA-N 2-chloro-7h-purine Chemical compound ClC1=NC=C2NC=NC2=N1 JBMBVWROWJGFMG-UHFFFAOYSA-N 0.000 description 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 2
- ZGGXQXLFNHDLLG-UHFFFAOYSA-N 3-(4-fluorophenyl)-2-(morpholin-4-ylmethyl)chromen-4-one Chemical compound C1=CC(F)=CC=C1C(C(C1=CC=CC=C1O1)=O)=C1CN1CCOCC1 ZGGXQXLFNHDLLG-UHFFFAOYSA-N 0.000 description 2
- PNWSHHILERSSLF-UHFFFAOYSA-N 4-methylbenzene-1,3-dicarboxylic acid Chemical compound CC1=CC=C(C(O)=O)C=C1C(O)=O PNWSHHILERSSLF-UHFFFAOYSA-N 0.000 description 2
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 2
- 229960005531 AMG 319 Drugs 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 2
- 206010009137 Chronic sinusitis Diseases 0.000 description 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 2
- 208000027932 Collagen disease Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000013382 Gelatinases Human genes 0.000 description 2
- 108010026132 Gelatinases Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 2
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 2
- 241000508269 Psidium Species 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- VCFBPAOSTLMYIV-SANMLTNESA-N [(1s)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)ethyl] 3-(cyclopropylmethoxy)-4-(methanesulfonamido)benzoate Chemical compound CS(=O)(=O)NC1=CC=C(C(=O)O[C@@H](CC=2C(=C[N+]([O-])=CC=2Cl)Cl)C=2C=C(OCC3CC3)C(OC(F)F)=CC=2)C=C1OCC1CC1 VCFBPAOSTLMYIV-SANMLTNESA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 210000001132 alveolar macrophage Anatomy 0.000 description 2
- 150000003863 ammonium salts Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 2
- 229960003728 ciclesonide Drugs 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960000676 flunisolide Drugs 0.000 description 2
- 229960000289 fluticasone propionate Drugs 0.000 description 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 229960001361 ipratropium bromide Drugs 0.000 description 2
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 2
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- KWRYMZHCQIOOEB-LBPRGKRZSA-N n-[(1s)-1-(7-fluoro-2-pyridin-2-ylquinolin-3-yl)ethyl]-7h-purin-6-amine Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=C(F)C=C2N=C1C1=CC=CC=N1 KWRYMZHCQIOOEB-LBPRGKRZSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000004963 pathophysiological condition Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 2
- 229950004432 rofleponide Drugs 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 229960000257 tiotropium bromide Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 2
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- QXVNPMGNZYNOFF-UHFFFAOYSA-N 2-[1-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)ethyl]-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=CC2=C(Cl)N=CN=C2N1C(C)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 QXVNPMGNZYNOFF-UHFFFAOYSA-N 0.000 description 1
- BTTUXUIQQBLIQE-UHFFFAOYSA-N 2-fluoro-7h-purine Chemical compound FC1=NC=C2NC=NC2=N1 BTTUXUIQQBLIQE-UHFFFAOYSA-N 0.000 description 1
- XPLIUIMHBPMEQW-UHFFFAOYSA-N 2-fluoro-n-propan-2-ylbenzamide Chemical compound CC(C)NC(=O)C1=CC=CC=C1F XPLIUIMHBPMEQW-UHFFFAOYSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- KIZQNNOULOCVDM-UHFFFAOYSA-M 2-hydroxyethyl(trimethyl)azanium;hydroxide Chemical compound [OH-].C[N+](C)(C)CCO KIZQNNOULOCVDM-UHFFFAOYSA-M 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001076 Acute sinusitis Diseases 0.000 description 1
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- 206010049153 Allergic sinusitis Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 101150015280 Cel gene Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- QMXOFBXZEKTJIK-UHFFFAOYSA-N Glycinol Natural products C1=C(O)C=C2OCC3(O)C4=CC=C(O)C=C4OC3C2=C1 QMXOFBXZEKTJIK-UHFFFAOYSA-N 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000035756 Infantile asthma Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- PGBFYLVIMDQYMS-UHFFFAOYSA-N Methyl thiophene-2-carboxylate Chemical compound COC(=O)C1=CC=CS1 PGBFYLVIMDQYMS-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010056626 Pseudopolyp Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010052568 Urticaria chronic Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- YPFLFUJKZDAXRA-UHFFFAOYSA-N [3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate Chemical compound O1C2=CC(OS(=O)(=O)C)=CC=C2C(NC(N)=O)=C1C(=O)C1=CC=C(Cl)C=C1Cl YPFLFUJKZDAXRA-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- TVWAEQRFKRTYIG-JIDHJSLPSA-N acetic acid;4-[(1r)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol Chemical compound CC(O)=O.C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1 TVWAEQRFKRTYIG-JIDHJSLPSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 1
- 229960001164 apremilast Drugs 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229950005953 camsilate Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 231100000294 dose-dependent toxicity Toxicity 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229950004949 duvelisib Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000009841 epithelial lesion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960001469 fluticasone furoate Drugs 0.000 description 1
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 1
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229950008462 lirimilast Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 description 1
- 229940125386 long-acting bronchodilator Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- WNYIBZHOMJZDKN-UHFFFAOYSA-N n-(2-acetamidoethyl)acetamide Chemical compound CC(=O)NCCNC(C)=O WNYIBZHOMJZDKN-UHFFFAOYSA-N 0.000 description 1
- 208000016366 nasal cavity polyp Diseases 0.000 description 1
- 230000035781 nonspecific defense system Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960001609 oxitropium bromide Drugs 0.000 description 1
- LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002423 protozoacide Substances 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JHLVEBNWCCKSGY-UHFFFAOYSA-N tert-butyl n-methylcarbamate Chemical compound CNC(=O)OC(C)(C)C JHLVEBNWCCKSGY-UHFFFAOYSA-N 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 229950003899 tofimilast Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 229960004026 vilanterol Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 238000007805 zymography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
Abstract
本发明涉及一种治疗自体免疫、呼吸性和/或炎性疾病或病状(例如牛皮癣、类风湿性关节炎、哮喘、COPD)的方法。所述方法包括施用PI3Kδ抑制剂或双重PI3Kδ-γ抑制剂和PDE4抑制剂。本发明还涉及含有PI3Kδ或双重PI3Kδ-γ抑制剂和PDE4抑制剂的药物组合物。
Description
本申请要求2012年11月8日提交的印度专利申请号2762/CHE/2012以及2012年11月8日提交的4688/CHE/2012的权益,其各自是特此以引用方式整体并入。
技术领域
本发明涉及一种治疗自体免疫、呼吸性和/或炎性疾病或病状(诸如牛皮癣、类风湿性关节炎、哮喘以及COPD)的方法,其是通过施用PI3Kδ抑制剂或双重PI3Kδ-γ抑制剂和PDE4抑制剂。本发明还涉及含有PI3Kδ或双重PI3Kδ-γ抑制剂和PDE4抑制剂的药物组合物。
背景技术
自体免疫、呼吸性以及炎性疾病,诸如类风湿性关节炎(RA)、牛皮癣、全身性红斑狼疮(SLE)、慢性阻塞性肺病(COPD)以及哮喘,是与免疫系统调控异常或活动过度相关联的慢性且经常进行性的疾病。这些疾病的起因和促成因素仍不明确。其特征在于先天性和适应性免疫系统的多种炎性细胞之间的复杂细胞相互作用。因此,这些病状的疾病病因学的异质性和复杂性使得寻找新的细胞靶标更具挑战性,因为不清楚细胞浸润中对比“无辜”旁观者,谁才是主要的病理起作用因素。
类风湿性关节炎(RA)是一种进行性、全身性自体免疫疾病,其特征在于多个关节慢性发炎,伴有相关联的全身性症状,诸如疲劳。这种发炎引起关节疼痛、僵硬以及肿胀,从而因骨和软骨破坏而致使关节功能丧失,经常会导致进行性残疾。患有RA的患者发展其它全身性并发症的可能性增大,所述并发症诸如骨质疏松症、贫血以及其它影响肺和皮肤的病症。所述疾病还影响平均预期寿命,使得寿命缩短3到7年。
有多种治疗可供用于管理RA。一些解决了RA的征象和症状,其它治疗的目的在于更改病程并且积极地影响RA的全身效应,诸如疲劳和贫血。
现行治疗包括使用:
生物制剂:这些生物制剂是遗传工程改造的药物,其靶向特异性细胞表面标记物或称为细胞因子的免疫系统中的信使物质,所述细胞因子是由细胞产生以便在炎性应答过程中调控其它细胞。生物制剂靶向的特异性细胞因子的实例为肿瘤坏死因子α(TNFα)。
传统疾病改善抗风湿药物(DMARD):这些药物是非特异性的免疫压制药物,旨在对抗RA的征象和症状,并且减缓进行性关节破坏。这些治疗经常彼此组合使用,或组合生物药剂使用,以便改进患者应答。
糖皮质类固醇(皮质类固醇):这些是与皮质醇有关的抗炎性药物,皮质醇是一种体内天然产生的、通过抵消炎症而起作用的类固醇。然而,糖皮质类固醇的副作用,包括高血糖、骨质疏松症、高血压、体重增长、白内障、睡眠问题、肌肉损失以及对感染的易感性,限制了其使用。
非类固醇抗炎性药物(NSAID):这些药物管理RA的征象和症状,诸如减少疼痛、肿胀以及发炎,但不改变病程或减缓关节破坏的进行。
还存在多种靶向免疫系统的其它组分的RA疗法。这些疗法包括靶向有助于减少关节以及全身发炎和RA进行的替换性细胞因子诸如白介素-6(IL-6)的生物性治疗。
哮喘是儿童中最常见的慢性疾病,并且还影响数百万的成人。全世界有大约23.5千万人罹患这种疾病。然而,哮喘的起因尚未充分了解。
慢性阻塞性肺病(COPD)是一种非常普遍的病状,并且是全世界发病率和死亡率的主要起因。随着疾病进行,患有COPD的患者可能趋向于频繁加剧,从而导致患者焦虑、健康状况恶化、肺功能下降以及死亡率增大。这些使得呼吸功能恶化的事件导致卫生保健利用、住院和成本增大。更糟糕的是,频繁加剧与肺功能的更快速下降相关联,进而缩短预期寿命。
根据慢性阻塞性肺疾病全球倡议(GOLD)的推荐,COPD的一线疗法是长效β-激动剂、长效毒蕈碱拮抗剂以及吸入型皮质类固醇。然而,这些药物减少与疾病相关联的症状和加剧,而不是靶向其分子和细胞基础。因此,仍然需要对COPD疗法的进一步改进。
磷酸肌醇-3激酶(PI3K)属于一类细胞内脂质激酶,其使肌醇磷脂(PI)的肌醇环的3位羟基磷酸化,从而产生脂质第二信使。有四种I类PI3K同工型——α、β、δ以及γ。
IC87114(2-((6-氨基-9H-嘌呤-9-基)甲基)-5-甲基-3-邻甲苯基喹唑啉-4(3H)-酮)是一种特异性PI3Kδ抑制剂(Sadhu,J.Immunology,1;170(5):2647-2654,2003;国际公布号WO 2010/111432以及美国公布号2010/0249155和2010/0168139)。
CAL-101(艾代拉里斯(Idelalisib))、TGR-1202、AMG-319以及INCB040093已报告为PI3Kδ的抑制剂并且正处于积极临床研发中。IPI-145(杜威利斯(duvelisib))和CAL130已经报告为PI3Kδ/γ的双重抑制剂,IPI-145正处于针对癌症和哮喘的临床研究以及组合氨甲蝶呤针对RA的临床研究中。
磷酸二酯酶-4(PDE4)抑制是COPD治疗的一种途径。罗氟司特(Roflumilast),一种新型PDE4抑制剂,其减少COPD中的气道发炎,如通过痰嗜中性粒细胞和嗜伊红性粒细胞计数所评定。然而,罗氟司特展现出剂量依赖性毒性,这限制了罗氟司特在较高剂量下的使用。Calverley,P,Rabe K,等人,Roflumilast in Symptomatic ChronicObstructive Pulmonary Disease:Two Randomized Clinical Trials.TheLancet 2009;374:685-694;以及Fabbri,L,Calverley,P,等人,Roflumilastin Moderate to Severe Chronic Obstructive Pulmonary Disease Treatedwith Longacting Bronchodilators:Two Randomized Clinical Trials.TheLancet 2009;374:695-703。
另外,Celgene已在治疗牛皮癣性关节炎中针对PDE-4抑制剂阿普司特(aprelimilast)的两项III期研究中显示出阳性结果。
另一种PDE4抑制剂是来自Anacor Pharmaceuticals的AN2728,其已完成针对特异性皮炎的II期研究。最近,Chiesi Group宣布成功完成了对CHF6001的I期试验,CHF6001是一种吸入式PDE4抑制剂,其被研发用于治疗炎性呼吸性病症,诸如慢性阻塞性肺病(COPD)和哮喘。
然而,就功效和毒性而论,PDE4抑制剂具有窄的治疗窗口。
尽管当前可用的干预疗法,仍然需要用于自体免疫病症诸如RA和牛皮癣以及呼吸性病症诸如哮喘和COPD的改进的医学治疗。
因此,本发明的目的是提供活性增强的、用于治疗呼吸性和/或炎性疾病和病状的新型药物组合物和方法。
发明内容
本发明涉及一种治疗自体免疫、呼吸性和/或炎性疾病或病状诸如类风湿性关节炎(RA)或慢性阻塞性肺病(COPD)的方法。所述方法包括施用以下各项的组合:(i)PI3Kδ或双重PI3Kδ和γ抑制剂;以及(ii)PDE4抑制剂。已意外发现PI3Kδ或双重PI3Kδ和γ抑制剂与PDE-4抑制剂协同作用(即,所述组合展现出活性显著大于基于PI3Kδ或双重PI3Kδ和γ抑制剂以及PDE-4抑制剂单独各自的个别活性将预期的活性)。PI3Kδ或双重PI3Kδ和γ抑制剂以及PDE4抑制剂可共同施用(例如,通过在单个剂型中具有两者,或同时或连续施用单独的剂型)。这个组合特别可用于治疗哮喘、过敏性鼻炎、非过敏性鼻炎、RA、COPD以及特异性皮炎。
一个实施方案为一种治疗自体免疫、呼吸性和/或炎性疾病或病状(诸如RA或COPD)的方法,其包括向有需要的患者施用PI3Kδ抑制剂和PDE4抑制剂。优选地,施用治疗有效量的PI3Kδ抑制剂和PDE4抑制剂。
另一实施方案为一种治疗自体免疫、呼吸性和/或炎性疾病或病状(诸如RA或COPD)的方法,其包括向有需要的患者施用双重PI3Kδ和γ抑制剂以及PDE4抑制剂。优选地,施用治疗有效量的双重PI3Kδ和γ抑制剂以及PDE4抑制剂。
另一实施方案为一种药物组合物,其包含(i)PI3Kδ或双重PI3Kδ和γ抑制剂;以及(ii)PDE4抑制剂。所述药物组合物可用于治疗自体免疫、呼吸性以及炎性疾病和病状,诸如治疗RA和COPD。
在一个实施方案中,药物组合物包含PI3Kδ抑制剂和PDE4抑制剂。在另一实施方案中,药物组合物包含双重PI3Kδ和γ抑制剂以及PDE4抑制剂。在一个优选实施方案中,药物组合物包含治疗有效量的PI3Kδ或双重PI3Kδ和γ抑制剂以及PDE4抑制剂。
本文所述的方法和组合物允许用较少量的活性剂来治疗自体免疫、呼吸性和/或炎性疾病和病状,进而允许成本节省、减少副作用,并且允许以更有效的方式持续较长时间段进行治疗。
在一个实施方案中,PI3Kδ或双重PI3Kδ和γ抑制剂是式(I)化合物:
或其互变异构体、其N-氧化物、其药学上可接受的酯、其前药或其药学上可接受的盐,其中:
每次出现的R独立地选自氢、卤素、-ORa、CN、取代的或未取代的C1-6烷基、取代的或未取代的C2-6烯基、取代的或未取代的C2-6炔基、取代的或未取代的C3-8环烷基以及取代的或未取代的杂环基团;
R1和R2可为相同或不同的,并且独立地选自氢、卤素以及取代的或未取代的C1-6烷基,或均直接结合至同一原子的R1和R2可接合以形成氧代基团(=O)或取代的或未取代的、饱和或不饱和的3-10员环(包括R1和R2结合的碳原子),所述环可任选地包含一个或多个可相同或不同并且选自O、NRa以及S的杂原子;
Cy1为选自以下的单环基团:取代的或未取代的环烷基、取代的或未取代的杂环基团、取代的或未取代的芳基以及取代的或未取代的杂芳基;
Cy2选自取代的或未取代的杂环基团、取代的或未取代的芳基以及取代的或未取代的杂芳基;
L1不存在或选自-(CRaRb)q-、-O-、-S(=O)q-、-NRa-或-C(=Y)-;
每次出现的Ra和Rb可相同或不同并且独立地选自氢、卤素、羟基、氰基、取代的或未取代的(C1-6)烷基、-NRcRd(其中Rc和Rd独立地为氢、卤素、羟基、氰基、取代的或未取代的(C1-6)烷基以及(C1-6)烷氧基)以及-ORc(其中Rc为取代的或未取代的(C1-6)烷基),或当Ra和Rb直接结合至同一原子时,其可接合以形成氧代基团(=O)或形成取代的或未取代的、饱和或不饱和的3-10员环(包括Ra和Rb直接结合的所述同一原子),所述环可任选地包含一个或多个可相同或不同并且选自O、NRd(其中Rd为氢或取代的或未取代的(C1-6)烷基)或S的杂原子;
Y选自O、S以及NRa;
n为1、2、3或4;并且
q为0、1或2。
在一个实施方案中,式(I)化合物为式(II)化合物:
或其互变异构体、其N-氧化物、其药学上可接受的酯、其前药或其药学上可接受的盐,其中R、R1、R2、L1、Cy1以及Cy2如以上对于式(I)所定义。
在另外的实施方案中,式(I)化合物选自式(IA-I)、(IA-II)、(IA-III)以及(IA-IV)化合物:
或其互变异构体、其N-氧化物、其药学上可接受的酯、其前药或其药学上可接受的盐,其中:
R、Cy1、R1、R2、n以及q如以上所定义;
每次出现的X独立地选自CR3或N;并且
每次出现的R3独立地选自氢、羟基、卤素、羧基、氰基、硝基、取代的或未取代的烷基、取代的或未取代的烷氧基、取代的或未取代的烯基、取代的或未取代的炔基、取代的或未取代的芳基、取代的或未取代的芳基烷基、取代的或未取代的环烷基、取代的或未取代的环烷基烷基、取代的或未取代的环烯基烷基、取代的或未取代的环烯基、取代的或未取代的杂芳基、取代的或未取代的杂芳基烷基、取代的或未取代的杂环、取代的杂环基烷基环、取代的或未取代的胍、-COORx、-C(O)Rx、-C(S)Rx、-C(O)NRxRy、-C(O)ONRxRy、-NRyRz、-NRxCONRyRz、-N(Rx)SORy、-N(Rx)SO2Ry、-(=N-N(Rx)Ry)、-NRxC(O)ORy、-NRxRy、-NRxC(O)Ry-、-NRxC(S)Ry、-NRxC(S)NRyRz、-SONRxRy-、-SO2NRxRy-、-ORx、-ORxC(O)NRyRz、-ORxC(O)ORy-、-OC(O)Rx、-OC(O)NRxRy、-RxNRyC(O)Rz、-RxORy、-RxC(O)ORy、-RxC(O)NRyRz、-RxC(O)Rx、-RxOC(O)Ry、-SRx、-SORx、-SO2Rx以及-ONO2,其中以上各基团中的Rx、Ry以及Rz可为氢、取代的或未取代的烷基、取代的或未取代的烷氧基、取代的或未取代的烯基、取代的或未取代的炔基、取代的或未取代的芳基、取代的或未取代的芳基烷基、取代的或未取代的环烷基、取代的或未取代的环烷基烷基、取代的或未取代的环烯基、取代的或未取代的杂芳基、取代的或未取代的杂芳基烷基、取代的或未取代的杂环、取代的或未取代的杂环基烷基环或取代的或未取代的氨基,或Rx、Ry以及Rz中的任意两者可接合以形成取代的或未取代的饱和或不饱和的3-10员环,所述环可任选地包含可相同或不同并且选自O、NRf(其中Rf为氢或取代的或未取代的烷基)或S的杂原子。
在优选实施方案中,本发明涉及治疗自体免疫、呼吸性和/或炎性疾病或病状的方法,其包括施用PI3Kδ或双重,PI3Kδ和γ抑制剂与PDE4抑制剂的组合,其中如上所述PI3Kδ或双重PI3Kδ和γ抑制剂为式(I)、(II)、(IA-I)、(IA-II)、(IA-III)或(IA-IV)的化合物。
在另一优选实施方案中,本发明涉及包含PI3Kδ或双重PI3Kδ和γ抑制剂以及PDE4抑制剂的药物组合物,其中如上所述,PI3Kδ或双重PI3Kδ和γ抑制剂为式(I)、(II)、(IA-I)、(IA-II)、(IA-III)或(IA-IV)的化合物。
在优选实施方案中,式(I)化合物选自:
2-[(6-氨基-9H-嘌呤-9-基)甲基]-6-溴-3-苯基-4H-苯并吡喃-4-酮;
6-溴-2-(吗啉代甲基)-3-苯基-4H-苯并吡喃-4-酮;
6-溴-2-(吗啉代甲基)-3-苯基-4H-苯并吡喃-4-酮盐酸盐;
2-[(6-氨基-9H-嘌呤-9-基)甲基]-3-苯基-4H-苯并吡喃-4-酮;
2-(吗啉代甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-(吗啉代甲基)-3-苯基-4H-苯并吡喃-4-酮盐酸盐;
2-[(1H-苯并[d]咪唑-1-基)甲基]-6-溴-3-苯基-4H-苯并吡喃-4-酮;
6-溴-2-[(4-甲基-1H-苯并[d]咪唑-1-基)甲基]-3-苯基-4H-苯并吡喃-4-酮;
2-[(1H-苯并[d]咪唑-1-基)甲基]-3-苯基-4H-苯并吡喃-4-酮;
2-[(4-甲基-1H-苯并[d]咪唑-1-基)甲基]-3-苯基-4H-苯并吡喃-4-酮;
2-[(6-氯-9H-嘌呤-9-基)甲基]-3-苯基-4H-苯并吡喃-4-酮;
6-溴-2-[(6-氯-9H-嘌呤-9-基)甲基]-3-苯基-4H-苯并吡喃-4-酮;
2-((9H-嘌呤-6-基硫代)甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-[(1H-咪唑-1-基)甲基]-3-苯基-4H-苯并吡喃-4-酮;
2-[(9H-嘌呤-6-基硫代)甲基]-6-溴-3-苯基-4H-苯并吡喃-4-酮;
2-((4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-6-溴-3-苯基-4H-苯并吡喃-4-酮;
2-[(6-氨基-9H-嘌呤-9-基)甲基]-6-溴-3-(4-氟苯基)-4H-苯并吡喃-4-酮;
2-[(6-氨基-9H-嘌呤-9-基)甲基]-3-(4-氟苯基)-4H-苯并吡喃-4-酮;
6-溴-3-(4-氟苯基)-2-(吗啉代甲基)-4H-苯并吡喃-4-酮;
6-溴-3-(4-氟苯基)-2-(吗啉代甲基)-4H-苯并吡喃-4-酮盐酸盐;
3-(4-氟苯基)-2-(吗啉代甲基)-4H-苯并吡喃-4-酮;
3-(4-氟苯基)-2-(吗啉代甲基)-4H-苯并吡喃-4-酮盐酸盐;
2-[(6-氨基-9H-嘌呤-9-基)甲基]-6-溴-3-邻甲苯基-4H-苯并吡喃-4-酮;
7-[(6-溴-4-氧代-3-苯基-4H-苯并吡喃-2-基)甲基]-1,3-二甲基-1H-嘌呤-2,6(3H,7H)-二酮;
2-(1-(6-氨基-9H-嘌呤-9-基)乙基)-6-溴-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(9H-嘌呤-6-基硫代)乙基)-6-溴-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-9H-嘌呤-9-基)乙基)-3-苯基-4H-苯并吡喃-4-酮;
(S)-2-(1-(9H-嘌呤-6-基氨基)乙基)-6-溴-3-苯基-4H-苯并吡喃-4-酮;
2-((9H-嘌呤-6-基氨基)甲基)-6-溴-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-6-溴-3-苯基-4H-苯并吡喃-4-酮;
2-((6-氨基-9H-嘌呤-9-基)甲基)-6-甲氧基-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-9H-嘌呤-9-基)乙基)-6-溴-3-(2-氟苯基)-4H-苯并吡喃-4-酮;
2-((6-氨基-9H-嘌呤-9-基)甲基)-6-溴-3-(2-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-9H-嘌呤-9-基)丙基)-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-9H-嘌呤-9-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((6-氨基-9H-嘌呤-9-基)甲基)-3-(2-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-9H-嘌呤-9-基)乙基)-3-(2-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-9H-嘌呤-9-基)丙基)-3-(2-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-9H-嘌呤-9-基)丙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-9H-嘌呤-9-基)丙基)-3-(4-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-9H-嘌呤-9-基)丙基)-6-氟-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-9H-嘌呤-9-基)乙基)-3-(4-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-9H-嘌呤-9-基)乙基)-6-氟-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-苯基-4H-苯并吡喃-4-酮;
2-((9H-嘌呤-6-基氨基)甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-9H-嘌呤-9-基)乙基)-3-邻甲苯基-4H-苯并吡喃-4-酮;
2-((9H-嘌呤-6-基氨基)甲基)-3-(2-氟苯基)-4H-苯并吡喃-4-酮;
2-((9H-嘌呤-6-基氨基)甲基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(S)-2-(1-(9H-嘌呤-6-基氨基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-9H-嘌呤-9-基)乙基)-6-氟-3-(2-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-9H-嘌呤-9-基)乙基)-3-(3,5-二氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-9H-嘌呤-9-基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(R)-2-(1-(9H-嘌呤-6-基氨基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(S)-2-(1-(9H-嘌呤-6-基氨基)乙基)-6-氟-3-苯基-4H-苯并吡喃-4-酮;
2-((4-氨基-3-碘-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-碘-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-碘-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((4-氨基-3-碘-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-6-氟-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-碘-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-6-氟-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-碘-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-碘-1H-吡唑并[3,4-d]嘧啶-1-基)丙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(吡啶-3-基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-羟基丙-1-炔基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(1H-吡唑-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-(羟基甲基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(1H-吲唑-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-氟苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-羟基丙基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-苯基-4H-苯并吡喃-4-酮;
N-(3-(4-氨基-1-((4-氧代-3-苯基-4H-苯并吡喃-2-基)甲基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯基)乙酰胺;
2-((4-氨基-3-(3-氟-5-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-氟-5-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-氟-5-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-氟-5-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(1H-吡唑-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-羟基-3-甲基丁-1-炔基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(1H-吡唑-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(S)-2-(1-(9H-嘌呤-6-基氨基)乙基)-3-苯基-4H-苯并吡喃-4-酮;
(S)-2-(1-(9H-嘌呤-6-基氨基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-5-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-5-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(1H-吲唑-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3,5-二甲基-1H-吡唑-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-甲基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(2-(羟基甲基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-氟-3-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-氟-3-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-羟基丙-1-炔基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氯-5-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氯-5-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-(三氟甲氧基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((6-氨基-9H-嘌呤-9-基)甲基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-氟-2-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-氟-2-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-氨基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-甲基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(2-氨基嘧啶-5-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(1H-吲哚-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-氯-3-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-氯-3-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(2-氯-5-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(2-氯-5-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3,4-二甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3,4-二羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-甲基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(1H-吲哚-5-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-甲基-1H-吲哚-5-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
甲基氨基甲酸叔丁基-(5-(4-氨基-1-(1-(3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)硫代苯-2-基)酯;
2-(1-(4-氨基-3-(5-(氨基甲基)硫代苯-2-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-甲基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-6-氟-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-甲基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-甲基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-6-氟-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-甲基-1H-吲唑-5-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
N-(4-(4-氨基-1-(1-(3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯基)乙酰胺;
2-(1-(4-氨基-3-(4-氨基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-甲基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(2,3-二氢苯并呋喃-5-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-乙基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-甲基-1H-吲哚-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(2-甲氧基嘧啶-5-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
4-(4-氨基-1-(1-(3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)噻吩-2-甲醛;
2-(1-(4-氨基-3-(5-(羟基甲基)硫代苯-3-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(2-甲基-1H-苯并[d]咪唑-5-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-甲基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)丙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-甲基-1H-吲哚-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((6-氨基-9H-嘌呤-9-基)甲基)-6-氟-3-苯基-4H-苯并吡喃-4-酮;
2-((6-氨基-9H-嘌呤-9-基)甲基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-氟-5-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-氟-5-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((9H-嘌呤-6-基氨基)甲基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((9H-嘌呤-6-基氨基)甲基)-6-氟-3-苯基-4H-苯并吡喃-4-酮;
(R)-2-(1-(9H-嘌呤-6-基氨基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(1H-吡唑-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-6-氟-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3,5-二氟-4-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3,5-二氟-4-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3,5-二氟-4-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3,5-二氟-4-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(+)-2-(1-(4-氨基-3-(3-甲基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(-)-2-(1-(4-氨基-3-(3-甲基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3,5-二甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-甲氧基-3,5-二甲基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(2-氟-5-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(2,3-二氢苯并[b][1,4]二氧杂环己烯-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(1-苄基-1H-吡唑-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(2-甲基吡啶-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3,4-二氢-2H-苯并[b][1,4]二氧杂环庚烯-7-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(6-吗啉代吡啶-3-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(二苯并[b,d]呋喃-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-(苄氧基)-3-氯苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氯-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-(二甲基氨基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-乙氧基-3-氟苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-(三氟甲氧基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(3-(4-乙酰基苯基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-(苄氧基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-(二甲基氨基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-(甲基磺酰基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-乙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(苯并[b]硫代苯-2-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(5-氯硫代苯-2-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3,5-二甲基异噁唑-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(呋喃-2-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-乙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氯-4-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(6-氟吡啶-3-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(嘧啶-5-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-(甲氧基甲基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(6-羟基萘-2-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(1-甲基-1H-吡唑-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
6-氟-3-(3-氟苯基)-2-(1-(4-甲氧基苯基氨基)乙基)-4H-苯并吡喃-4-酮;
2-(1-(4-氯-7H-吡咯并[2,3-d]嘧啶-7-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氯-1H-吡唑并[3,4-b]吡啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氯-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氯-5H-吡咯并[3,2-d]嘧啶-5-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(1,3-二甲基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(2,3-二甲基-2H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(6-甲氧基萘-2-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(苯并[b]硫代苯-3-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(2,4-二甲氧基嘧啶-5-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(6-乙氧基萘-2-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
3-(4-氨基-1-(1-(3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)-N-环丙基苯甲酰胺;
2-(1-(4-氨基-3-(3-(吗啉-4-羰基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-(二氟甲氧基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
5-(4-氨基-1-(1-(3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)呋喃-2-甲醛;
(S)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(R)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(S)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(R)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(6-氨基-9H-嘌呤-9-基)甲基)-3-(3-氟苯基)-5-甲氧基-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-3-(3-氟苯基)-5-甲氧基-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-氟-5-甲氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-((4-氨基-3-(3-氟-5-羟基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)甲基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(+)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(-)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-甲基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(+)-2-(1-(4-氨基-3-(3-甲基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(-)-2-(1-(4-氨基-3-(3-甲基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(1H-吡唑-4-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-9H-嘌呤-9-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(4-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(苯并呋喃-2-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(9H-嘌呤-6-基氨基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(+)-2-(1-(4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(-)-2-(1-(4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-(二氟甲氧基)-3-氟苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(1H-吡唑-4-基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-(四氢-2H-吡喃-4-基氧基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-异丙基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-(哌啶-4-基氧基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-(2-羟基乙基氨基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-(异丙基氨基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-(二甲基氨基)-3-氟苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-吗啉代苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(2-甲基-1H-苯并[d]咪唑-5-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-(4-甲基哌嗪-1-基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-(二甲基氨基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(4-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-(二氟甲氧基)-3-氟苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(4-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-(二氟甲氧基)-3-氟苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-甲基-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-乙基-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-异丙基-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(苯并[b]硫代苯-2-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-吗啉代-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(二甲基氨基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(哌啶-1-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(6-异丙氧基吡啶-3-基)-1H-吡唑并[3,4-d]嘧啶-1-基乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(甲基硫代)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮4-甲基苯磺酸盐;
2-(1-(4-氨基-3-(3-甲基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮4-甲基苯磺酸盐;
2-(1-(4-氨基-3-(4-(1-二苯甲基氮杂环丁烷-3-基氧基)-3-氟苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-(三氟甲氧基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-(氧杂环丁烷-3-基氧基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(吡咯烷-1-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
N-(4-(4-氨基-1-(1-(5-氟-3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯基)异丁酰胺;
2-(1-(4-氨基-3-(4-异丁基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-异丙氧基-3-甲基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-(5,6-二氢-4H-1,3-噁嗪-2-基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
4-(4-氨基-1-(1-(5-氟-3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)-N-甲基苯磺酰胺;
4-(4-氨基-1-(1-(5-氟-3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)-2-氟-N-异丙基苯甲酰胺;
2-(1-(4-氨基-3-(4-(5-(甲基氨基)-1,3,4-噻二唑-2-基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
N-(4-(4-氨基-1-(1-(5-氟-3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)苄基)甲磺酰胺;
4-(4-氨基-1-(1-(5-氟-3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)-N-异丙基苯磺酰胺;
4-(4-氨基-1-(1-(5-氟-3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)-N-环丙基苯磺酰胺;
2-(1-(4-氨基-3-(2-异丙氧基嘧啶-5-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(R)/(S)-2-(1-(4-氨基-3-(3-氟-4-吗啉代苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
4-(4-氨基-1-(1-(5-氟-3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯磺酰胺;
4-(4-氨基-1-(1-(5-氟-3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)噻吩-2-甲酸甲酯;
2-(1-(4-氨基-3-(5-甲基硫代苯-2-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(1H-吡咯并[2,3-b]吡啶-5-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
4-(4-氨基-1-(1-(5-氟-3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)-3-氟苯甲酸甲酯;
2-(1-(9H-嘌呤-6-基氨基)丙基)-5-氟-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-羟基丙-1-炔基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(S)/(R)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮4-甲基苯磺酸盐;
(+)-2-(1-(9H-嘌呤-6-基氨基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(9H-嘌呤-6-基氨基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(R)/(S)-2-(1-(4-氨基-3-(3-氟-4-吗啉代苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-甲氧基-3,5-二甲基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-(甲氧基甲基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(咪唑并[1,2-a]吡啶-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(5-(4-氨基-1-(1-(5-氟-3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)呋喃-2-基)甲基氨基甲酸叔丁酯;
2-(1-(4-氨基-3-(2,4-二甲基噻唑-5-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(5-(吗啉代甲基)硫代苯-2-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-(5-氨基-1,3,4-噻二唑-2-基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(-)-2-(1-(9H-嘌呤-6-基氨基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(1,3-二甲基-1H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(2,3-二甲基-2H-吲唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
N-(4-(4-氨基-1-(1-(5-氟-3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)-2-氟苯基)异丁酰胺;
N-(4-(4-氨基-1-(1-(5-氟-3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)-2-氟苯基)乙酰胺;
2-(1-(4-(二甲基氨基)-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
5-氟-2-(1-(3-(3-氟-4-异丙氧基苯基)-4-(甲基氨基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
5-氟-2-(1-(3-(3-氟-4-异丙氧基苯基)-4-吗啉代-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
N-(2-氟-4-(1-(1-(5-氟-3-(4-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-4-吗啉代-1H-吡唑并[3,4-d]嘧啶-3-基)苯基)异丁酰胺;
N-(2-氟-4-(1-(1-(5-氟-3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-4-吗啉代-1H-吡唑并[3,4-d]嘧啶-3-基)苯基)异丁酰胺;
(S)/(R)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮磺酸盐;
(S)/(R)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(S)/(R)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮樟脑磺酸盐;
2-(1-(4-氨基-3-(4-(二氟甲氧基)-3-氟苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(1H-吡唑-4-基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-吗啉代苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-吗啉代苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(4-氟苯基)-4H-苯并吡喃-4-酮;
(S)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(4-氟苯基)-4H-苯并吡喃-4-酮;
(R)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(4-氟苯基)-4H-苯并吡喃-4-酮;
(S)-2-(1-(4-氨基-3-(4-(二氟甲氧基)-3-氟苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(4-氟苯基)-4H-苯并吡喃-4-酮;
(R)-2-(1-(4-氨基-3-(4-(二氟甲氧基)-3-氟苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(4-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-(二甲基氨基)-3-(3-氟-4-吗啉代苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
5-氟-2-(1-(3-(3-氟-4-吗啉代苯基)-4-(甲基氨基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(S)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-苯基-4H-苯并吡喃-4-酮;
(R)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-苯基-4H-苯并吡喃-4-酮;
(S)-2-(1-(4-氨基-3-(4-(二氟甲氧基)-3-氟苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-苯基-4H-苯并吡喃-4-酮;
(R)-2-(1-(4-氨基-3-(4-(二氟甲氧基)-3-氟苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-苯基-4H-苯并吡喃-4-酮;
(+)-5-氟-2-(1-(3-(3-氟-4-异丙氧基苯基)-4-(甲基氨基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(-)-5-氟-2-(1-(3-(3-氟-4-异丙氧基苯基)-4-(甲基氨基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-2-氟-9H-嘌呤-9-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(6-氨基-2-氟-9H-嘌呤-9-基)乙基)-5-氟-3-(4-氟苯基)-4H-苯并吡喃-4-酮;
5-氟-3-(4-氟苯基)-2-(1-(6-吗啉代-9H-嘌呤-9-基)乙基)-4H-苯并吡喃-4-酮;
5-氟-3-(4-氟苯基)-2-(1-(6-(4-甲基哌嗪-1-基)-9H-嘌呤-9-基)乙基)-4H-苯并吡喃-4-酮;
2-(1-(6-(二甲基氨基)-9H-嘌呤-9-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(6-(二甲基氨基)-9H-嘌呤-9-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
5-氟-3-(3-氟苯基)-2-(1-(3-(3-甲基-1H-吲唑-6-基)-4-吗啉代-1H-吡唑并[34-d]嘧啶-1-基)乙基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氯-4-吗啉代苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(+)-2-(1-(4-氨基-3-(4-异丙氧基-3-甲基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(-)-2-(1-(4-氨基-3-(4-异丙氧基-3-甲基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(S)/(R)-5-氟-2-(1-(3-(3-氟-4-异丙氧基苯基)-4-吗啉代-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氯-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(2-甲基苯并[d]噁唑-6-基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
5-氟-3-(3-氟苯基)-2-(1-(6-吗啉代-9H-嘌呤-9-基)乙基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-3-(3-氟苯基)-5-吗啉代-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-吗啉代-3-苯基-4H-苯并吡喃-4-酮;
6-(4-氨基-1-(1-(5-氟-3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)异吲哚啉-1-酮;
5-(4-氨基-1-(1-(5-氟-3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)异吲哚啉-1-酮;
2-(1-(3-(4-乙酰基-3-氟苯基)-4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
5-氟-3-(3-氟苯基)-2-(1-(6-(4-甲基哌嗪-1-基)-9H-嘌呤-9-基)乙基)-4H-苯并吡喃-4-酮;
(S)-2-(1-(4-氨基-3-(3-氯-4-吗啉代苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(R)-2-(1-(4-氨基-3-(3-氯-4-吗啉代苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
N-(3-(4-氨基-1-(1-(5-氟-3-(3-氟苯基)-4-氧代-4H-苯并吡喃-2-基)乙基)-1H-吡唑并[3,4-d]嘧啶-3-基)苯基)甲磺酰胺;
(S)-2-(1-(6-(二甲基氨基)-9H-嘌呤-9-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(R)-2-(1-(6-(二甲基氨基)-9H-嘌呤-9-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(9H-嘌呤-6-基氨基)乙基)-5-氟-3-(2-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(4-乙氧基-3-(三氟甲基)苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)丙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(S)-5-氟-3-(3-氟苯基)-2-(1-(2-甲氧基-9H-嘌呤-6-基氨基)乙基)-4H-苯并吡喃-4-酮;
(R)-5-氟-3-(3-氟苯基)-2-(1-(2-甲氧基-9H-嘌呤-6-基氨基)乙基)-4H-苯并吡喃-4-酮;
(S)/(R)-5-氟-2-(1-(2-氟-9H-嘌呤-6-基氨基)乙基)-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(S)/(R)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-甲基-3-苯基-4H-苯并吡喃-4-酮;
2-(1-(9H-嘌呤-6-基氨基)乙基)-5-氟-3-邻甲苯基-4H-苯并吡喃-4-酮;以及
其药学上可接受的盐。
在另一优选实施方案中,式(I)化合物为选自以下的PI3Kδ抑制剂:
2-((6-氨基-9H-嘌呤-9-基)甲基)-5-甲基-3-邻甲苯基喹唑啉-4(3H)-酮(IC87114);
(S)-2-(1-((9H-嘌呤-6-基)氨基)丙基)-5-氟-3-苯基喹唑啉-4(3H)-酮(CAL-101,艾代拉里斯);
INCB040093;
AMG 319;
(S)-2-(1-(9H-嘌呤-6-基氨基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮(化合物C);
(S)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;以及
其药学上可接受的盐。
在另一优选实施方案中,式(I)化合物为选自以下的双重PI3Kδ和γ抑制剂:
(S)-3-(1-((9H-嘌呤-6-基)氨基)乙基)-8-氯-2-苯基异喹啉-1(2H)-酮(IPI-145);
(+)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮(化合物A1);
(-)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;以及
其药学上可接受的盐。
在优选实施方案中,PDE-4抑制剂为阿普司特或罗氟司特。
另一实施方案为一种用于治疗自体免疫、呼吸性或炎性疾病或病状的试剂盒,所述试剂盒包括:
(i)PI3Kδ或PI3Kδ和γ抑制剂;以及(ii)PDE4抑制剂,其处于单一药物组合物或单独的药物组合物中;
(ii)任选地,用于使用PI3Kδ或PI3Kδ和γ抑制剂以及PDE4抑制剂治疗自体免疫、呼吸性或炎性疾病或病状的用法说明书;以及
(iii)任选地,用于放置所述一种或多种药物组合物的容器。
附图说明
图1描绘化合物A以及其与30和300nM化合物B的组合对抑制TNFα自U-937细胞释放的影响。**p<0.01并且***p<0.001(对比化合物A)。
图2描绘化合物A以及其与300nM化合物B的组合对MMP-9自THP-1细胞释放的影响。
图3描绘有和没有化合物B(30nM)情况下,化合物A对pAkt(S473)在用香烟烟雾提取物(CSE)刺激的分化U937细胞中的表达的影响。
图4描绘化合物A以及其与化合物B(300nM)的组合对抑制弹性蛋白酶自人嗜中性粒细胞释放的影响。**p<0.01并且***p<0.001(对比化合物A)。
图5描绘化合物A以及其与化合物B(300nM)的组合对CSE诱导后A549细胞增殖的影响。*表示p<0.05,**表示p<0.01,并且***表示p<0.001,与施用化合物A单独相比。
图6描绘化合物A以及其与化合物B(300nM)的组合对A549细胞中细胞凋亡的抑制作用。
图7A、7B以及7C分别描绘化合物A、化合物C以及其组合对嗜中性粒细胞浸润的抑制作用。
图8A、8B以及8C描绘化合物A、化合物A1以及其组合对嗜中性粒细胞浸润的抑制作用。
图9描绘化合物A、化合物C以及其组合在雄性Balb/c小鼠的急性香烟烟雾诱导的细胞浸润中对巨噬细胞浸润的抑制作用。
图10描绘化合物A、化合物A1以及其组合在雄性Balb/c小鼠的急性香烟烟雾诱导的细胞浸润中对巨噬细胞浸润的抑制作用。
图11描绘化合物A、化合物C以及其组合在雄性Balb/c小鼠的慢性香烟烟雾诱导的细胞浸润中对巨噬细胞浸润的抑制作用。
具体实施方式
定义
当本文中使用范围用于物理特性诸如分子量或化学特性诸如化学式时,旨在包括范围的所有组合和子组合以及其中的具体实施方案。当提及数量或数值范围时,术语“约”意指所提及的数量或数值范围是实验变异(或统计实验误差)范围内的近似值,并且因此数量或数值范围可例如在所陈述数量或数值范围的1%与15%之间变化。术语“包含(comprising)”(和有关术语诸如“包含(comprise)”或“包含(comprises)”或“具有(having)”或“包括(including)”)包括那些实施方案,例如物质、组合物、方法或过程等等的“由所述特征组成”或“基本上由所述特征组成”的任何构成的实施方案。
通篇以下缩写和术语具有所指示的含义:PI3-K=磷酸肌醇3-激酶;PI=磷脂酰肌醇;并且MeI=甲基碘。
除非另有指示,否则本文所使用的缩写具有其在化学和生物领域内的常规含义。
术语“取代的或未取代的”,“烷基”、“烷氧基”、“烯基”、“炔基”、“芳基”、“芳基烷基”、“环烷基”、“环烷基烷基”、“环烯基烷基”、“环烯基”、“杂芳基”、“杂芳基烷基”、“杂环”(或杂环基)以及“杂环基烷基”如国际专利申请号PCT/IB2010/002804和PCT/US2012/36594所定义。本文所述的PI3K抑制剂的合适药学上可接受的盐包括国际专利申请号PCT/IB2010/002804和PCT/US2012/36594中所述的那些。
术语“有效量”或“治疗有效量”是指本文所述的化合物或化合物组合足以实现所打算的应用、包括但不限于疾病治疗的量,如以下所定义。治疗有效量可取决于以下各项而变:所打算的应用(体外或体内)或所治疗的受试者和疾病病状,例如受试者的体重和年龄、疾病病状的严重程度、施用方式等等,其可由本领域普通技术人员容易地确定。所述术语还适用于将在靶细胞中诱导特定应答、例如减少血小板粘附和/或细胞迁移的剂量。具体剂量将取决于所选的特定化合物、待遵守的给药方案、是否组合其它化合物施用、施用时机、被施用其的组织以及携带其的物理递送系统而变。
如本文所用,术语“治疗(treatment和treating)”是指获得有益或所需结果的途径,所述有益或所需结果包括但不限于治疗益处和/或预防益处。治疗益处意指根除或改善所治疗的潜在病症。另外,通过根除或改善与潜在病症相关联的一种或多种生理学症状,以使得在患者中观察到好转来实现治疗益处,尽管患者可能仍然罹患潜在的病症。对于预防益处,可将组合物施用给有风险发展特定疾病的患者,或施用给报告疾病的一种或多种生理学症状的患者,即使可能尚未作出对此疾病的诊断。
如本文所用的术语“治疗作用”包涵如以上所述的治疗益处和/或预防益处。预防作用包括延迟或消除疾病或病状出现、延迟或消除疾病或病状的症状发作,减缓、停止或逆转疾病或病状进行,或其任何组合。
术语“受试者”或“患者”是指动物,诸如哺乳动物,例如人。本文所述的方法可用于人体治疗学和兽用应用。在一些实施方案中,患者为哺乳动物,并且在一些实施方案中,患者为人。对于兽用目的,术语“受试者”和“患者”包括但不限于农畜,包括牛、绵羊、猪、马和山羊;伴侣动物,诸如狗和猫;野外动物和/或动物园动物;实验室动物,包括小鼠、大鼠、兔、豚鼠和仓鼠;以及禽类,诸如鸡、火鸡、鸭以及鹅。
如应用于生物活性剂的术语“选择性抑制(selective inhibition或selectively inhibit)”是指与脱靶信号传导活性相比,药剂经由直接或间接与靶标相互作用选择性地减少靶信号传导活性的能力。
如本文所用,术语“PI3-激酶δ选择性抑制剂”一般是指与PI3K家族的其它同工酶(α、β以及γ)相比,更有效地抑制PI3-激酶δ同工酶的活性的化合物。例如,PI3-激酶δ选择性抑制剂可指展现出的关于δI型PI3-激酶的50%抑制浓度(IC50)比抑制剂关于其余的其它I型PI3-激酶(即,α、β以及γ)的IC50低至少10倍、至少20倍、至少50倍、至少100倍的化合物。
如本文所用,术语“双重PI3-激酶δ和γ抑制剂”一般是指与PI3K家族的其它同工酶相比,更有效地抑制PI3-激酶δ与γ同工酶两者的活性的化合物。因此,与为“非选择性PI3K抑制剂”的常规PI3K抑制剂诸如渥曼青霉素(wortmannin)和LY294002相比,PI3-激酶δ和γ双重抑制剂化合物对于PI3-激酶δ和γ的选择性更大。
例如,双重PI3-激酶δ和γ选择性抑制剂可指展现出的关于δ和γI型PI3-激酶的50%抑制浓度(IC50)比抑制剂关于其余的其它I型PI3-激酶(即,α和β)的IC50低至少10倍、至少20倍、至少50倍、至少100倍的化合物。
本发明的治疗方法包括用于治疗与炎性应答相关联的病状的方法。“炎性应答”的特征在于发红、发热、肿胀以及疼痛(即发炎)并且典型地涉及组织损伤或破坏。炎性应答通常为由组织损伤或破坏引出的局部化的保护性应答,其用来破坏、稀释或隔开(隔离)损伤性试剂和损伤的组织。炎性应答显然与白细胞流入和/或白细胞(例如嗜中性粒细胞)趋化性相关联。炎性应答可由感染病原性生物和病毒,非感染性方式诸如创伤或心肌梗塞或中风后再灌注、对外来抗原的免疫应答以及自体免疫疾病产生。可用根据本发明的方法和化合物治疗的炎性应答包涵与特异性防御系统的反应相关联的病状以及与非特异性防御系统的反应相关联的病状。
本发明的治疗方法包括用于治疗与炎性细胞活化相关联的病状的方法。“炎性细胞活化”是指炎性细胞(包括但不限于单核细胞、巨噬细胞、T淋巴细胞、B淋巴细胞、粒细胞(多形核白细胞,包括嗜中性粒细胞、嗜碱粒细胞以及嗜伊红性粒细胞)、肥大细胞、树突细胞、朗氏细胞以及内皮细胞)中通过对增殖细胞应答的刺激(包括但不限于细胞因子、抗原或自身抗体)进行的诱导,可溶性介体(包括但不限于细胞因子、氧自由基、酶、前列腺素类或血管活性胺)的产生,或新的或增大数量的介体(包括但不限于主要组织相容性抗原或细胞粘附分子)的细胞表面表达。本领域技术人员应了解这些细胞中的这些表型中的一种或其组合的活化可促使炎性病状起始、维持或加剧。
如本文中所用“自体免疫疾病”是指任何组的病症,其中组织损伤与体液或细胞介导的针对身体自身成分的应答相关联。
“过敏性”疾病一般是指由过敏导致的任何症状、组织损害或组织功能丧失。
“关节炎性”疾病一般是指特征在于可归因于多种病因学的关节炎性病变的任何疾病。
“皮炎”一般是指特征在于可归因于多种病因学的皮肤发炎的一大类皮肤病中的任一种。
如本文所用,术语“共同施用”、“组合施用”以及其在语法上的等同物包涵向动物施用两种或更多种药剂,使得药剂和/或其代谢物均同时存在于动物体内。共同施用包括以独立的组合物同时施用、以独立的组合物在不同时刻施用、或以两种药剂均存在的一种组合物进行施用。
如本文所用,术语“药学上可接受的盐”包括衍生自诸如以下的无机碱的盐:Li、Na、K、Ca、Mg、Fe、Cu、Zn以及Mn;诸如以下的有机碱的盐:N,N′-二乙酰基乙二胺、葡萄糖胺、三乙基胺、胆碱、氢氧化物、二环己基胺、二甲双胍、苄基胺、三烷基胺以及硫胺素;诸如以下的手性碱的盐:烷基苯基胺、甘氨醇以及苯基甘氨醇;诸如以下的天然氨基酸的盐:甘氨酸、丙氨酸、缬氨酸、亮氨酸、异亮氨酸、正亮氨酸、酪氨酸、胱氨酸、半胱氨酸、甲硫氨酸、脯氨酸、羟基脯氨酸、组氨酸、鸟氨酸、赖氨酸、精氨酸以及丝氨酸;本发明化合物与烷基卤、烷基硫酸酯诸如MeI和(Me)2SO4的季铵盐;诸如以下的非天然氨基酸的盐:如D-异构体或取代的氨基酸;胍的盐;以及取代的胍的盐,其中取代基选自硝基、氨基、烷基、烯基、炔基,铵或取代的铵盐以及铝盐。适当时,盐可包括酸加成盐,其为硫酸盐、硝酸盐、磷酸盐、高氯酸盐、硼酸盐、氢卤化物、乙酸盐、酒石酸盐、马来酸盐、柠檬酸盐、反丁烯二酸盐、丁二酸盐、棕榈酸盐、甲磺酸盐、苯甲酸盐、水杨酸盐、苯磺酸盐、抗坏血酸盐、甘油磷酸盐以及酮戊二酸盐。
PI3Kδ和双重PI3Kδ和γ抑制剂
可用于本文所述的组合物和方法中的PI3-激酶δ选择性抑制剂以及双重PI3-激酶δ和γ抑制剂的实例包括但不限于CAL-101(艾代拉里斯)、IPI-145(杜威利斯)以及以下各项中公开的化合物:国际公布号WO 2012/151525、美国专利公布号2011/0118257和2012/0289496、2010年11月3日提交的国际专利申请号PCT/IB2010/002804、2012年5月4日提交的PCT/US2012/36594、2013年7月2日提交的PCT/US2013/055434以及2013年7月2日提交的美国专利申请号13/933,856。以下各项还公开另外的非限制性实例:国际公布号WO2001/081346、WO 2003/035075、WO 2005/113554、WO 200/113556、WO 2006/024666、WO 2008/118454、WO 2008/118455、WO2009/010530,WO 2009/064802、WO 2009/088986、WO 2009/088990、WO 2009/147189、WO 2010/005558、WO 2010/051042、WO2010/051043、WO 2010/056320、WO 2010/057048、WO 2010/092015、WO 2010/092962、WO 2010/096389、WO 2010/102958、WO2010/110685、WO 2010/110686、WO 2010/111432、WO 2010/123931、WO 2010/135014、WO 2010/136491、WO 2010/138589、WO2010/144513、WO 2010/151737、WO 2010/151740、WO 2010/151791、WO 2011/005119、WO 2011/008302、WO 2011/008487、WO2011/011550、WO 2011/012883、WO 2011/021038、WO 2011/022439、WO 2011/041399、WO 2011/041634、WO 2011/048111、WO2011/048936、WO 2011/055215、WO 2011/075268、WO 2011/075630、WO 2011/075643、WO 2011/101429、WO 2011/123751、WO2011/130342、WO 2011/156759、WO 2011/163195、WO 2012/003262、WO 2012/003264、WO 2012/003271、WO 2012/003274、WO2012/003278、WO 2012/003283、WO 2012/004299、WO 2012/007493、WO 2012/0135009、WO 2012/020762、WO 2012/021696、WO2012/032067、WO 2012/037204、WO 2012/037226、WO 2012/040634、WO 2012/044641、WO 2012/052753、WO 2012/055846、WO2012/061696、WO 2012/064973、WO 2012/068343、WO 2012/087784、WO 2012/087881、WO 2012/097000、WO 2012/107465、WO2012/116237、WO 2012/121953、WO 2012/125510、WO 2012/125629、WO 2012/126901、WO 2012/135160、WO 2012/135166、WO2012/135175、WO 2012/140419、WO 2012/146666、WO 2012/146667、WO 2012/148548、WO 2012/151525、US 2012/0220575、US2012/0238587、WO 2013/012915、WO 2013/012918、WO 2013/032591、WO 2013/033569、WO 2013/052699、WO 2013/057711、WO2013/067141、WO 2013/067306、WO 2013/071264、WO 2013/078441、WO 2013/082540、WO 2013/090725、WO 2013/116562、WO2013/132270、WO 2013/134288、WO 2013/136075以及WO2013/136076。描述PI3K抑制剂和其制备的这些公布各自是以引用方式并入本文中。
PDE-4抑制剂
用于本文所述的组合物和方法中的合适PDE-4抑制剂包括但不限于恩丙茶碱(enprofylline)、茶碱、氨茶碱、胆茶碱、阿普司特(apremilast)、罗氟司特、阿瑞罗(ariflo)(西洛司特(cilomilast))、妥非司特(tofimilast)、普马芬群(pumafentrine)、利米司特(lirimilast)、阿罗茶碱(arofylline)、阿替唑兰(atizorame)、奥格米坦(oglemilastum)、D-4418、Bay-198004、BY343、CP-325,366、D-4396(Sch-351591)、AWD-12-281(GW-842470)、NCS-613、CDP-840、D-4418、PD-168787、T-440、T-2585、V1 1294A、CI-1018、CDC-801、CDC-3052、D-22888、YM-58997、Z-15370、N-(3,5-二氯-1-氧代-吡啶-4-基)-4-二氟甲氧基-3-环丙基甲氧基苯甲酰胺、(-)-p-[(4aR*、10bS*)-9-乙氧基-1,2,3,4,4a,10b-六氢-8-甲氧基-2-甲基苯并[s][1,6]-二氮杂萘-6-基]-N,N-二异丙基苯甲酰胺、(R)-(+)-1-(4-溴苄基)-4-[(3-环戊氧基)-4-甲氧基苯基]-2-吡咯烷酮、3-(环戊氧基-4-甲氧基苯基)-1-(4-N′-[N-2-氰基-S-甲基-异硫代脲基]苄基)-2-吡咯烷酮、顺[4-氰基-4-(3-环戊氧基-4-甲氧基苯基)环己烷-1-羧酸]、2-甲酯基-4-氰基-4-(3-环丙基甲氧基-4-二氟甲氧基苯基)环己烷-1-酮、顺[4-氰基-4-(3-环丙基甲氧基-4-二氟甲氧基苯基)环己烷-1-醇]、乙酸(R)-(+)-乙基[4-(3-环戊氧基-4-甲氧基苯基)吡咯烷-2-亚基]酯、乙酸(S)-(-)-乙基[4-(3-环戊氧基-4-甲氧基苯基)吡咯烷-2-亚基]酯、9环戊基-5,6-二氢-7-乙基-3-(2-噻吩基)-9H-吡唑并[3,4c]-1,2,4-三唑并[4,3a]吡啶以及9-环戊基-5,6-二氢-7-乙基-3-(叔丁基)-9H-吡唑并[3,4c]-1,2,4-三唑并[4,3a]吡啶,其任选地呈外消旋形式、作为对映异构体、非对映异构体或作为药学上可接受的盐、溶剂合物或水合物,或WO 2012/016845和WO2012/016889中所公开的化合物。
在优选实施方案中,PDE4抑制剂选自茶碱、氨茶碱、胆茶碱、罗氟司特以及阿普司特。在另一优选实施方案中,PDE4抑制剂为罗氟司特。在另一实施方案中,PDE4抑制剂为阿普司特。
药物组合物
在一方面,本发明提供包含以下各项的药物组合物:PI3Kδ或双重PI3Kδ和γ双重抑制剂以及PDE4抑制剂,和任选地一种或多种药学上可接受的载体或赋形剂。
在一个实施方案中,药物组合物包含治疗有效量的PI3Kδ或双重PI3Kδ和γ抑制剂以及治疗有效量的PDE4抑制剂。在另一实施方案中,药物组合物包含协同有效量的(i)PI3Kδ或双重PI3Kδ和γ抑制剂;以及(ii)PDE4抑制剂。例如,药物组合物可包含约0.1μg至约2g、优选地约1μg至约1000mg、更优选地约10μg至约500mg、诸如约100μg至约100mg的PI3Kδ或双重PI3Kδ和γ抑制剂,以及约0.1μg至约500mg、优选地约1μg至约100mg、更优选地约10μg至约50mg、诸如约10μg至约10mg的PDE4抑制剂。
药物组合物还可包含一种或多种另外的活性成分,诸如可用于预防和/或治疗呼吸性疾病的那些,诸如β2-激动剂(例如沙丁胺醇(salbutamol)、沙美特罗(salmeterol)以及维兰特罗(vilanterol));皮质类固醇(诸如丙酸氟替卡松(fluticasone propionate)或糠酸氟替卡松、氟尼缩松(flunisolide)、糠酸莫米松(mometasone furoate)、罗氟奈德(rofleponide)以及环索奈德(ciclesonide);以及抗胆碱能或抗毒蕈碱剂(诸如异丙托溴铵(ipratropium bromide)、氧托溴铵(oxytropiumbromide)、噻托溴铵(tiotropium bromide)以及奥昔布宁(oxybutynin)),以及其组合。
药物载体和/或赋形剂可选自稀释剂、填充剂、盐、崩解剂、粘合剂、润滑剂、助流剂、湿润剂、控释基质、着色剂、调味剂、缓冲剂、稳定剂、增溶剂以及其组合。
本发明的药物组合物可单独或与一种或多种另外的活性剂组合施用,所述另外的活性剂诸如以上所述的那些。本发明的药物组合物可与一种或多种其它活性剂一起或以顺序方式进行施用。需要时,本发明的药物组合物和其它活性成分可共同施用,或两者可顺序施用以便将它们用作一个组合。
本发明的化合物和药物组合物可通过能够将化合物递送至作用部位的任何途径施用,诸如但不限于口服、鼻内、表面(例如经皮)、十二指肠内、胃肠外(包括静脉内、动脉内、肌肉内、血管内、腹膜内或通过注射或输注)、皮内、通过乳房内、鞘内、眼内、眼球后、肺内(例如气雾化药物)或皮下(包括贮库施用以用于长期释放,例如包埋在脾被膜、脑下或角膜中)、舌下、经肛门、经直肠、经阴道或通过手术植入(例如包埋在脾被膜、脑下或角膜中)或通过吸入。
组合物可以固体、半固体、液体或气态形式施用,或可呈干燥粉末、诸如冻干形式。药物组合物可以便于递送的形式进行封装,所述形式包括例如固体剂型,诸如胶囊、小药囊、扁囊剂、明胶、纸、片剂、栓剂、丸剂、药片、锭剂以及糖锭。封装的类型一般将取决于所需施用途径。如同经皮制剂,还涵盖植入式持续释放制剂。在一个优选实施方案中,药物组合物为固体口服剂型,诸如片剂或胶囊。
在另一实施方案中,药物组合物适合吸入(例如通过气雾化)。
本发明还涉及根据本文所述的任一实施方案的药物组合物,其用于治疗自体免疫、呼吸性和/或炎性疾病以及病状。
本发明的另一实施方案涉及一种治疗自体免疫、呼吸性和/或炎性疾病以及病状的方法,其包括向有需要的受试者施用治疗有效量的根据本文所述的任一实施方案的药物组合物。
本发明的另一实施方案涉及根据本文所述的任一实施方案的药物组合物的用途,其用于制造供治疗有需要的受试者的自体免疫、呼吸性和/或炎性疾病以及病状的药剂。
在根据本文所述的任一实施方案的药物组合物中,PI3Kδ抑制剂可呈溶剂合物、水合物或与药学上可接受的酸或碱的盐形式。
在根据本文所述的任一实施方案的药物组合物中,双重PI3Kδ和γ抑制剂可呈溶剂合物、水合物或与药学上可接受的酸或碱的盐形式。
在根据本文所述的任一实施方案的药物组合物中,PDE4抑制剂可呈溶剂合物、水合物或与药学上可接受的酸或碱的盐形式。
在一个实施方案中,本发明涉及一种根据本文所述的任一实施方案的药物组合物,其中PDE4抑制剂为罗氟司特。
本发明的另一特定实施方案涉及根据本文所述的任一实施方案的药物组合物,其中PDE4抑制剂为阿普司特。
本发明的另一特定实施方案涉及根据本文所述的任一实施方案的药物组合物,其中PDE4抑制剂为茶碱。
治疗方法
本发明的另一实施方案为一种治疗以下疾病的方法:与免疫系统有关的疾病(例如自体免疫疾病)、涉及发炎的疾病或病症(例如哮喘、慢性阻塞性肺病、类风湿性关节炎、炎性肠病、肾小球性肾炎、神经炎性疾病、多发性硬化症、葡萄膜炎以及免疫系统病症)、癌症或其它增生性疾病、肝脏疾病或病症或肾脏疾病或病症。所述方法包括施用有效量的PI3Kδ或双重PI3Kδ和γ双重抑制剂以及PDE4抑制剂。
PI3Kδ或双重PI3Kδ和γ双重抑制剂以及PDE4抑制剂(和任选地其它活性成分)可并入单一药物组合物中并施用,或者可以单独的药物组合物施用,这些单独的药物组合物可同时或在不同时刻施用。
待施用的每种化合物的量取决于所治疗的受试者(诸如哺乳动物或特别是人类)、病症或病状的严重程度、施用率、化合物的性质以及处方医师的判断。在一个实施方案中,PI3Kδ或PI3Kδ和γ双重抑制剂的有效剂量为约0.001至约100mg/kg体重/天,例如约1至约35mg/kg/天,按单一或分次剂量。对于70kg的人来说,这将相当于约0.05至7g/天、优选地约0.05至约2.5g/天。在一个实施方案中,PDE4抑制剂的有效剂量为约0.001至约100mg/kg体重/天,例如约0.1至约100mcg/kg/天,按单一或分次剂量(例如约7至约7000mcg/天或约10至约1000mcg/天)。可按单一或多个剂量(例如每天两次或三次)施用有效量的PI3Kδ或PI3Kδ和γ双重抑制剂和/或PDE4抑制剂。
在另一实施方案中,PI3Kδ或双重PI3Kδ和γ抑制剂以及PDE4抑制剂各自按范围为约0.01mg至约1000mg的量施用。
在另一实施方案中,每天施用约0.05mg至约7g的PI3Kδ或PI3Kδ和γ双重抑制剂以及约7至约7000mcg(例如约10至约1000mcg)的PDE4抑制剂。例如,当PDE4抑制剂为罗氟司特时,每天施用约100至约2000mcg的罗氟司特(优选地口服或通过吸入)。在另一实施方案中,每天施用约200、300、400、500或600mcg的罗氟司特(优选地口服或通过吸入)。
PI3Kδ或PI3Kδ和γ双重抑制剂以及PDE4抑制剂可口服或通过吸入施用。在一个实施方案中,PI3Kδ或PI3Kδ和γ双重抑制剂通过吸入施用,并且PDE4抑制剂口服施用。在另一实施方案中,PI3Kδ或PI3Kδ和γ双重抑制剂以及PDE4抑制剂均口服施用。在另一实施方案中,PI3Kδ或PI3Kδ和γ双重抑制剂口服施用,并且PDE4抑制剂通过吸入施用。在另一实施方案中,PI3Kδ或PI3Kδ和γ双重抑制剂以及PDE4抑制剂均通过吸入施用。
在本文所述的任一方法的另外实施方案中,PI3Kδ或双重PI3Kδ和γ抑制剂以及PDE4抑制剂是口服或通过吸入施用。例如,PI3Kδ或双重PI3Kδ和γ抑制剂可并且PDE4抑制剂是口服施用。PI3Kδ或双重PI3Kδ和γ抑制剂可并且PDE4抑制剂是通过吸入施用。PI3Kδ或双重PI3Kδ和γ抑制剂中的一者口服施用,并且PDE4抑制剂通过吸入施用,或者PI3Kδ或双重PI3Kδ和γ抑制剂中的一者通过吸入施用,并且PDE4抑制剂口服施用。
在本文所述的任一方法的另外实施方案中,PI3Kδ或双重PI3Kδ和γ抑制剂以及PDE4抑制剂以按重量计约1∶100至约100∶1的比率施用。
在一个实施方案中,治疗有效量的PI3Kδ或双重PI3Kδ和γ抑制剂是每天两次至每三周一次进行施用,并且治疗有效量的PDE4抑制剂是每天两次至每三周一次进行施用。
可通过本发明的化合物进行治疗的免疫病症的实例包括但不限于牛皮癣、类风湿性关节炎、血管炎、炎性肠病、皮炎、骨关节炎、哮喘、炎性肌病、过敏性鼻炎、阴道炎、间质性膀胱炎、硬皮病、骨质疏松症、湿疹,同种异体移植或异种移植(器官、骨髓、干细胞以及其它细胞和组织)移植物排斥反应、移植物对抗宿主疾病、红斑狼疮、炎性疾病、I型糖尿病、肺纤维化、皮肌炎、舍格伦氏综合症(Sjogren′ssyndrome)、甲状腺炎(例如桥本氏(Hashimoto′s)和自体免疫甲状腺炎)、重症肌无力、自体免疫溶血性贫血、多发性硬化症、囊肿性纤维化、慢性复发性肝炎、原发性胆汁性肝硬变、过敏性结膜炎以及特异性皮炎。
本发明的另一实施方案涉及一种治疗选自以下的疾病或病症的方法:呼吸性疾病和病状,诸如气道和肺部疾病,其伴有增多的或改变的粘液产生,和/或气道的炎性和/或阻塞性疾病,诸如急性支气管炎、慢性支气管炎、慢性阻塞性支气管炎(COPD)、咳嗽、肺气肿、过敏性或非过敏性鼻炎或窦炎、慢性窦炎或鼻炎、鼻息肉病、慢性鼻窦炎、急性鼻窦炎、哮喘、过敏性支气管炎、牙槽炎、农民病、高反应性气道、由例如细菌或病毒或蠕虫或真菌或原生动物或其它病原体感染引起的支气管炎或肺炎、小儿哮喘、支气管扩张症、肺纤维化、成人呼吸窘迫综合征、支气管和肺水肿、由不同起源引起的支气管炎或肺炎或间质性肺炎,所述起源例如呼吸、吸入毒性气体、蒸气,由心脏衰竭、X射线、放射、化学疗法引起的支气管炎或肺炎或间质性肺炎,与胶原性疾病相关联的支气管炎或肺炎或间质性肺炎,所述胶原性疾病例如红斑狼疮、全身性硬皮病、非肺纤维化、特发性肺纤维化(IPF),不同起源的间质性肺病或间质性肺炎,包括石棉肺、硅肺、伯克氏肉样瘤、肉芽肿病、囊肿性纤维化或粘稠物阻塞症,或a-1抗胰蛋白酶缺乏;或选自炎性疾病和病状,诸如各种起源的胃肠道炎性疾病,诸如炎性假息肉、克罗恩氏(Crohn′s)病、溃疡性结肠炎,关节炎性疾病,诸如类风湿性关节炎,或口鼻咽、皮肤或眼睛的过敏性炎性疾病,诸如特异性皮炎、季节性和常年性慢性风疹、不明起因的荨麻疹和过敏性结膜炎;并且特别是选自哮喘、过敏性和非过敏性鼻炎、COPD以及特异性皮炎;其包括向有需要的患者施用治疗有效量的根据本文所述的任一实施方案的药物组合物。
本发明的另一实施方案涉及根据本文所述的任一实施方案的药物组合物的用途,其用于制造供治疗呼吸性和/或炎性疾病和病状的药剂,具体来说其中呼吸性和/或炎性疾病或病状是选自哮喘、过敏性和非过敏性鼻炎、COPD以及特异性皮炎。
本发明的另一实施方案涉及根据本文所述的任一实施方案的药物组合物,其用于治疗呼吸性和炎性疾病和病状的药剂,具体来说其中呼吸性和炎性疾病或病状是选自哮喘、过敏性和非过敏性鼻炎、COPD以及特异性皮炎。
现在将通过以下非限制性实施例进一步说明本发明。
实施例
如以下实施例中所述,化合物A为罗氟司特;化合物B为IC87114;化合物C为国际公布号WO 11/055215(PCT/2010/002804)的实施例74,并且化合物A1为国际公布号WO 2012/151525(PCT/US2012/036594)的实施例7。代表性实施例使用罗氟司特和阿普司特作为PDE-4抑制剂。
实施例1
PI3Kδ抑制剂与PDE-4抑制剂的组合研究
在这些研究中,化合物A用作PDE4抑制剂,并且化合物B和C用作PI3Kδ抑制剂。
TNFα的评估:将U937细胞按100,000细胞/孔接种在96孔板中,并且用所需浓度的化合物孵育30分钟,之后添加1μg/ml LPS。24小时后收集上清液,并且根据试剂盒制造商(eBioscience,USA)推荐的方案,通过ELISA评估TNFα浓度。简单地说,用100μl的1mg/ml TNFα涂覆抗体涂覆Nunc Maxisorp板。将上清液转移至板中,并且在37℃下孵育2h。添加抗-TNFα检测抗体和抗生物素蛋白-HRP,之后添加TMB底物。在450nm下在Fluostar Omega(BMG Labtech,NC,USA)上测量吸光度。
结果:结果显示在图1中。10μM化合物A(罗氟司特)与300或30nM化合物B(IC87114)的组合分别将TNFα释放有效减小达75%的58%的Emax。对于低至300nM化合物A浓度与300nM化合物B的组合观察到TNFα分泌的显著减小(p<0.01),从而指示在PI3Kδ抑制剂存在下,罗氟司特控制造成COPD加剧的细胞因子的调控。
量化基质金属蛋白酶(MMP)-9:通过酶谱法测定MMP-9的明胶酶活性。在含有0.1%明胶(Sigma,USA)的凝胶上分离上清液中的蛋白质(在用50ng PMA孵育THP-1细胞24h后)。通过在2.5%Triton X-100中孵育30min使凝胶复性、在含有10mM CaCl2和0.05%ZnCl2的底物缓冲液(50mMTris-HCl,pH 7.5)中在37℃下孵育过夜,并且用库马斯亮蓝(0.5%)染色。凝胶的蓝色背景中的透明区证明明胶酶活性存在。伴随每一种凝胶操作分子量标记(Fermentas,Lithuania)。使用ImageJ1.42(NIH,USA)计算带强度。
结果:结果显示在图2中。与空白孔相比,观察到因诱导MMP-9释放增大两倍。化合物A对于减小MMP-9的IC50为577nM,而化合物B单独在300nM下对于MMP-9释放无影响。然而,化合物B(300nM)与化合物A的存在有效加强了化合物A的作用,甚至是在最低测试浓度(0.1nM)下。
SDS-PAGE评估磷酸-Akt:通过用50ng/ml PMA诱导48h,U-937单核细胞分化成巨噬细胞。使细胞进行胰蛋白酶消化并且按100,000/孔的密度接种,并且在饥饿培养基中用CSE刺激2h。使用RIPA缓冲液制备溶解产物,并且通过SDS-PAGE操作,转移至PVDF膜,并且用磷酸-Akt(S473)抗体(Cell signaling,USA)、之后用抗-兔IgG(Cellsignaling,USA)探测。使用ImageJ 1.42(NIH,USA)计算带强度。
结果:结果显示在图3中。化合物A和化合物B分别以剂量依赖性方式抑制Akt磷酸化,其IC50值分别为1934和780nM。然而,组合30nM的化合物B,观察到化合物A的IC50(1.5nM)显著减小(约1290倍),从而指示根据MMP-9减少应答加强。
量化嗜中性粒细胞弹性蛋白酶:从当地血库获得血液。使用葡聚糖沉淀法获得嗜中性粒细胞。将细胞按100,000细胞/孔接种在96孔板中,用fMLP(1μM)和N-琥珀酰基-Ala-Ala-Ala-对-硝基苯胺(1μM)(Sigma)处理,并且孵育2h。通过在405nm下在Fluostar Omega(BMGLabtech,NC,USA)上测量吸光度测定孵育后所消化底物的强度。
结果:结果显示在图4中。化合物A抑制fMLP诱导的弹性蛋白酶释放,其IC50为10.2nM(Emax=43%),化合物B单独情况下的减少可忽略(300nM下为10%)。化合物A与300nM化合物B的组合导致Emax(65%)增大,同时化合物A的IC50相应减少至4.8nM。
细胞增殖测定:将A549细胞按10,000细胞/孔接种在96孔板中,并且用CSE孵育72h。通过评估添加100μgMTT并且在37℃下孵育4h后形成的可溶性甲腊(在DMSO中)的量测定细胞活力。去除培养基并且将晶体溶解在100μlDMSO中。在450nm下在Fluostar Omega(BMG Labtech,NC,USA)上测量吸光度。
结果:结果显示在图5中。化合物A与300nM化合物B的组合引起对CSE的抗增殖作用的显著逆转,其IC50为8.7nM。不希望受任何特定理论约束情况下,发明人推理PDE4抑制剂与PI3Kδ抑制剂的组合用来保护肺泡上皮细胞,进而最小化COPD的进行。
细胞周期分析:将A549细胞以100,000细胞/孔的密度接种在6孔板中,并且用CSE刺激72h。孵育后,将细胞固定在70%乙醇中,并且储存在4℃下直到分析。用Guava细胞周期试剂根据制造商的说明书进行染色。使用Guava个人细胞分析系统(Millipore,USA)获得细胞周期数据。
结果:结果显示在图6中。用化合物A处理导致对细胞凋亡的剂量依赖性抑制。使用化合物A与300nM化合物B的组合,这种下降显著进一步加强,从而指示此组合预防肺损害的潜在有用性。
总之,测定出用LPS/CSE后,分化U937巨噬细胞中TNFα、pAkt以及MMP-9的抑制作用。评估通过弹性蛋白酶活性活性的调节显现的嗜中性粒细胞功能性。还测定组合(化合物A和B)对CSE诱导的肺上皮细胞的细胞凋亡的保护作用。数据证明化合物A(PDE4抑制剂)与化合物B(PI3Kδ抑制剂)的组合在纳摩尔浓度下减小TNFα、pAkt以及MMP-9,并且效力比任一化合物单独大数倍。组合还显著增大对嗜中性粒细胞弹性蛋白酶的抑制,从而提供PI3Kδ抑制剂与PDE4抑制剂的组合在治疗COPD中的治疗益处的证据。
人全血(HWB)中LPS诱导的TNFα:用培养基稀释新鲜收集的HWB,并且用所需浓度的抑制剂孵育15min。添加LPS(1μg/ml)并且然后孵育24小时。收集上清液,并且使用eBioscience TNFαELISA试剂盒评估TNFα。尽管施用1000nM化合物C或2.5nM罗氟司特单独不会引起显著应答(TNFα分泌下降<10%),但两种化合物的组合在相同浓度下施用时导致TNFα分泌下降>30%,即组合的效力与单独施用的化合物C或罗氟司特的效力相比增大3倍以上,从而指示此组合在治疗炎性病症、特别是气道病症、牛皮癣以及RA中的协同作用和治疗合宜性。
PBMC中LPS诱导的TNFα:通过密度梯度使用Histopaque分离来自全血的PBMC(外周血单核细胞),并且用所需浓度的抑制剂孵育15分钟。添加LPS(1μg/ml),并且然后孵育24小时。收集上清液,并且使用eBioscience TNFαELISA试剂盒评估TNFα。尽管施用1000nM化合物C单独引起TNFα分泌下降20%,将1.25nM罗氟司特添加至1000nM化合物C导致TNFα分泌下降80%,即与化合物C单独的效力相比效力增大4倍,从而指示此组合在治疗炎性病症、特别是气道病症、牛皮癣以及RA中的协同作用和治疗合宜性。
雌性Wistar大鼠中脂多糖诱导的肺嗜中性粒细胞增多症:嗜中性粒细胞的夸大募集和随后活化对于气道和肺中数种炎性疾病的发展和病程可能是重要的,所述疾病诸如严重哮喘、COPD、囊肿性纤维化以及急性呼吸窘迫综合征。嗜中性粒细胞促成这些疾病的机制可包括诸如嗜中性粒细胞弹性蛋白酶的蛋白质水解酶和氧自由基的释放。释放时,这些试剂可在气道中引起支气管收缩、支气管高反应性、分泌过度、上皮损害以及组织重塑。
检疫期后,将禁食动物随机化并且根据其体重分成多个组。将测试化合物制备成媒介物中的悬浮液,所述媒介物包含0.5%甲基纤维素,其中Tween 80用作悬浮剂。通过经口强饲法以10mL/kg的体积施用化合物或媒介物。用氯胺酮将动物麻醉,并且按1mg/kg的剂量施用化合物30分钟后,气管内施用LPS溶液。LPS滴注6小时后,将动物在麻醉下放血,并且将导管插入气管,并且通过气管导管用5ml肝素化PBS(1单位/ml)的等分试样将肺灌洗4次(总体积20ml)。将支气管肺泡(BAL)流体储存在2-8℃下,直到测定总细胞和白细胞分类计数。将BAL流体离心(500×g,10min),并且将所得细胞沉淀再悬浮在0.5ml肝素化盐水中。使用细胞计数器在BAL流体或血液中测定白血球的总数,并且将其调整至1×106细胞/ml。手动计算细胞分类计数。使用细胞离心机3离心100微升细胞悬浮液以制备细胞抹片。使用血液染色溶液针对分化将细胞抹片染色,并且在显微镜下观察载玻片以根据形态特征鉴别嗜伊红性粒细胞。测定细胞抹片中300个白血球中的每种细胞类型的数量,并且表示为总细胞的百分比。计算BALF中嗜伊红性粒细胞的数量。
结果:结果显示在图7A、7B以及7C中。
罗氟司特的有效剂量:罗氟司特证明与对照组相比在0.3、1、3以及10mg/kg下对嗜中性粒细胞浸润的剂量依赖性抑制。抑制百分比分别为-7.89%、43.46%、68.02%以及92.21%,并且50%抑制(ED50)剂量为1.8mg/kg。
化合物C的有效剂量:与对照组相比,在口服施用化合物C后,在0.1、1、3以及10mg/kg下观察到对嗜中性粒细胞浸润的剂量依赖性抑制。抑制百分比分别为14.15%、57.76%、56.93%以及81.55%,并且50%抑制(ED50)剂量为1mg/kg。
各ED50剂量的罗氟司特与化合物C的组合:与对照组相比,罗氟司特或化合物C单独在1.8和1mg/kg剂量下分别示出对嗜中性粒细胞浸润有36.18%和36.56%的抑制作用。当将罗氟司特(1.8mg/kg)与化合物C(剂量为1mg/kg)相组合时,与对照组动物相比,对嗜中性粒细胞浸润的抑制增大至78.20%。
雄性Balb/c小鼠中急性香烟烟雾诱导的细胞浸润:在实验开始之前,使动物适应7天。基于体重,将动物随机分配至不同组中。第1天,通过口服途径对小鼠施用测试化合物或媒介物,并且30分钟后,将施用测试化合物的动物放置在全身暴露箱中。在第1天至第4天,使小鼠暴露至6支香烟的主流烟雾。暴露至每支香烟的烟雾持续10min(香烟在前2分钟完全燃尽并且之后是用动物呼吸器呼吸空气流),接下来20min用新鲜室内空气进行暴露。在每第二支香烟后,进行另外20min分钟间断,暴露至新鲜室内空气。使对照动物暴露至室内空气腔室。从第1天至第4天,通过口服途径对动物施用测试化合物。在第5天,最后一次香烟烟雾(CS)暴露24小时后,将动物在麻醉下放血,并且将导管插入气管,并且通过气管导管用0.5ml肝素化PBS(1单位/ml)的等分试样将肺灌洗4次(总体积2ml)。将所收集的支气管肺泡(BAL)流体储存在2-8℃下,直到测定总细胞和白细胞分类计数。将BAL流体离心(500×g,10min),并且将所得细胞沉淀再悬浮在0.5ml肝素化盐水中。使用血细胞计数器在BAL流体和血液中测定白血球的总数,并且将其调整至1×106细胞/ml。手动计算细胞分类计数。使用细胞离心机3离心40微升细胞悬浮液以制备细胞抹片。使用血液染色溶液针对分化将细胞抹片染色,并且在显微镜下观察,以根据形态特征鉴别每种细胞。测定细胞抹片中300个白血球中的每种细胞类型的数量,并且表示为百分比,并且计算各BAL流体中嗜中性粒细胞和巨噬细胞的数量。
结果:结果显示在图9中。
罗氟司特的有效剂量:罗氟司特证明与对照组相比在1、3以及10mg/kg下对巨噬细胞浸润的剂量依赖性抑制。抑制百分比分别为22.2%、51.00%以及69.11%并且50%抑制(ED50)剂量为3.5mg/kg。罗氟司特证明与对照组相比在1、3以及10mg/kg下对嗜中性粒细胞浸润的抑制作用。抑制百分比分别为70.85%、73.69%以及83.01%,并且考虑嗜中性粒细胞浸润的50%抑制剂量(ED50)用于组合研究。
化合物C的有效剂量:与对照组相比,在口服施用化合物C后,在1、3以及10mg/kg下观察到对巨噬细胞和嗜中性粒细胞浸润的剂量依赖性抑制。巨噬细胞浸润的抑制百分比分别为34.84%、42.09%以及61.77%,并且50%抑制(ED50)剂量为4.4mg/kg。化合物C证明与对照组相比在1、3以及10mg/kg下对嗜中性粒细胞浸润的抑制作用。抑制百分比分别为29.06%、62.38%以及74.25%,并且嗜中性粒细胞浸润的50%抑制(ED50)剂量为2.1mg/kg。
各ED50剂量的罗氟司特与化合物C的组合:与对照组相比,罗氟司特或化合物C单独在3.5和3mg/kg剂量下分别示出对巨噬细胞浸润有26.55%和30.01%的抑制作用。当将罗氟司特(3.5mg/kg)与化合物C(剂量为3mg/kg)相组合时,与对照组动物相比,对巨噬细胞浸润的抑制增大至99.89%。与对照组相比,罗氟司特或化合物C单独在3.5和3mg/kg剂量下分别示出对嗜中性粒细胞浸润有44.42%和41.47%的抑制作用。同样,与对照组相比,罗氟司特(3.5mg/kg)与化合物C(剂量为3mg/kg)的组合示出对嗜中性粒细胞浸润有88.34%的抑制。
雄性Balb/c小鼠中慢性香烟烟雾诱导的细胞浸润:在实验开始之前,使动物适应7天。基于体重,将动物随机分配至不同组中。在第1天至第11天,使小鼠暴露至4支香烟的主流烟雾。暴露至每支香烟的烟雾持续10min(每支香烟在前2分钟完全燃尽并且之后是用动物呼吸器呼吸空气流),接下来20min用新鲜室内空气进行暴露。在每第二支香烟后,进行另外20min分钟间断,暴露至新鲜室内空气。使对照动物暴露至室内空气腔室。在第6天至第11天,在30min的全身烟雾暴露之前,通过口服途径施用测试化合物。在第12天,最后一次香烟烟雾(CS)暴露24小时后,将动物在麻醉下放血,并且将导管插入气管,并且通过气管导管用0.5ml肝素化PBS(1单位/ml)的等分试样将肺灌洗4次(总体积2ml)。将所收集的支气管肺泡(BAL)流体储存在2-8℃下,直到测定总细胞和白细胞分类计数。将BAL流体离心(500×g,10min),并且将所得细胞沉淀再悬浮在0.5ml肝素化盐水中。使用血细胞计数器在BAL流体和血液中测定白血球的总数,并且将其调整至1×106细胞/ml。手动计算细胞分类计数。使用细胞离心机3离心40微升细胞悬浮液以制备细胞抹片。使用血液染色溶液针对分化将细胞抹片染色,并且在显微镜下观察,以根据形态特征鉴别每种细胞。测定细胞抹片中300个白血球中的每种细胞类型的数量,并且表示为百分比,并且计算各BAL流体中嗜中性粒细胞和巨噬细胞的数量。
结果:结果显示在图11中。
各ED50剂量的罗氟司特与化合物C的组合:与对照组相比,罗氟司特或化合物C单独在1和1mg/kg剂量下分别示出对巨噬细胞浸润有6.30%和-13.30%的抑制作用。当将罗氟司特(1mg/kg)与化合物C(剂量为1mg/kg)相组合时,与对照组动物相比,对巨噬细胞浸润的抑制增大至122.24%。与对照组相比,罗氟司特或化合物C单独在1mg/kg和1mg/kg剂量下分别示出对嗜中性粒细胞浸润有34.60%和4.08%的抑制作用。同样,与对照组相比,罗氟司特(1mg/kg)与化合物C(剂量为1mg/kg)的组合示出对嗜中性粒细胞浸润有77.78%的抑制。
实施例2
双重PI3Kδ和γ抑制剂与PDE-4抑制剂的组合研究
使用化合物A1作为双重PI3Kδ和γ抑制剂进行此研究。化合物A1展现出对于PI3Kδ与PI3Kγ酶,IC50值≤40nM。
MH-S(小鼠肺泡巨噬细胞)中LPS诱导的TNFα:MH-S表示在LPS诱导后分泌大量TNFα的小鼠肺泡巨噬细胞系。将细胞按150,000细胞/孔进行接种。添加罗氟司特之前15分钟,添加10nM化合物A1(最终浓度)。添加LPS(1μg/ml),并且然后孵育4小时。20小时后,收集上清液,并且使用ELISA试剂盒评估TNFα。化合物A1以剂量依赖性方式抑制TNFα,即COPD进行中所涉及的重要细胞因子。向PDE4抑制剂罗氟司特添加30nM化合物A1导致与罗氟司特单独的IC50相比,IC50降低数百倍,从而指示这一组合在气道病症中的协同作用和治疗合宜性。同样,尽管施用15nM化合物A1或130nM阿普司特单独不引起TNFα分泌显著下降(约10%),但两种化合物在相同浓度下的组合导致下降35%以上,因此提供这一组合在治疗炎性病症、特别是气道病症、牛皮鲜以及RA中的协同作用和治疗合宜性。
THP-1(人单核细胞)中LPS诱导的TNFα:THP-1表示具有高内源性pAKT水平并且在LPS诱导后分泌大量TNFα的单核细胞系。将细胞按150,000细胞/孔进行接种。添加罗氟司特之前15分钟,添加10nM化合物A1(最终浓度)。添加LPS(1μg/ml),并且然后孵育4小时。20小时后,收集上清液,并且使用ELISA试剂盒评估TNFα。化合物A1以剂量依赖性方式抑制TNFα,即COPD进行中所涉及的重要细胞因子。向PDE4抑制剂罗氟司特添加100nM化合物A1导致与罗氟司特单独的IC50相比,IC50降低数百倍,从而指示这一组合在治疗气道病症中的协同作用并且因此指示其治疗合宜性。
人全血(HWB)中Con A+PMA诱导的IFNγ:用培养基稀释新鲜收集的HWB,并且用所需浓度的抑制剂孵育15分钟。通过添加伴刀豆球蛋白A(25μg/ml)+醋酸佛波豆蔻酯(50ng/ml)诱导细胞因子释放。20小时后,收集上清液,并且使用ELISA试剂盒评估IFNγ。尽管施用10nM化合物A1单独不影响IFNγ分泌,但施用10nM化合物A1与罗氟司特的组合导致与罗氟司特单独的IC50相比,IC50下降3倍,从而指示这一组合在治疗气道病症、牛皮癣以及RA中的治疗合宜性。
人全血(HWB)中LPS诱导的TNFα:用培养基稀释新鲜收集的HWB,并且用所需浓度的抑制剂孵育15分钟。添加LPS(1μg/ml),并且然后孵育24小时。收集上清液,并且使用eBioscience TNFαELISA试剂盒评估TNFα。尽管施用100nM化合物A1单独不影响TNFα分泌,但施用100nM化合物A1与罗氟司特的组合导致与罗氟司特单独的IC50相比,IC50降低10倍以上,从而指示这一组合在治疗炎性病症,特别是气道病症、牛皮癣以及RA中的协同作用以及治疗合宜性。
PBMC中Con A+PMA诱导的IFNγ:通过密度梯度使用Histopaque分离来自全血的PBMC,并且用所需浓度的抑制剂孵育15分钟。通过添加伴刀豆球蛋白A(25μg/ml)+醋酸佛波豆蔻酯(50ng/ml)诱导细胞因子释放。20小时后,收集上清液,并且使用ELISA试剂盒评估IFNγ。尽管施用10nM化合物A1单独不影响IFNγ分泌,但添加10nM化合物A1与罗氟司特的组合导致与罗氟司特单独的IC50相比,IC50降低1.5倍,从而指示这一组合在治疗炎性病症,特别是气道病症、牛皮癣以及RA中的协同作用以及治疗合宜性。
PBMC中LPS诱导的TNFα:通过密度梯度使用Histopaque分离来自全血的PBMC,并且用所需浓度的抑制剂孵育15分钟。添加LPS(1μg/ml),并且然后孵育24小时。收集上清液,并且使用eBioscienceTNFαELISA试剂盒评估TNFα。尽管施用10nM化合物A1单独引起TNFα分泌下降25%,但添加10nM化合物A1与罗氟司特的组合导致与罗氟司特单独的IC50相比,IC50降低3倍,从而指示这一组合在治疗炎性病症,特别是气道病症、牛皮癣以及RA中的治疗合宜性。
雌性Wistar大鼠中脂多糖诱导的肺嗜中性粒细胞增多症:用化合物A1和罗氟司特进行如实施例1中所述的针对雌性Wistar大鼠中LPS诱导的肺嗜中性粒细胞增多症的程序。
结果:结果显示在图8A、8B以及8C中。
罗氟司特的有效剂量:罗氟司特证明与对照组相比在0.3、1、3以及10mg/kg下对嗜中性粒细胞浸润的剂量依赖性抑制。抑制百分比分别为-7.89%、43.46%、68.02%以及92.21%,并且50%抑制(ED50)剂量为1.8mg/kg。
化合物A1的有效剂量:口服施用化合物A1后,与对照组相比在0.1、1以及10mg/kg下观察到对嗜中性粒细胞浸润的剂量依赖性抑制。抑制百分比分别为17.83%、51.76%以及70.21%,并且50%抑制(ED50)剂量为1.3mg/kg。
各ED50剂量的罗氟司特和化合物A1的组合:与对照组相比,罗氟司特或化合物A1单独在1.8和1.3mg/kg剂量下分别示出对嗜中性粒细胞浸润有36.18%和43.02%的抑制作用。当将罗氟司特(1.8mg/kg)与化合物A1(剂量为1.3mg/kg)相组合时,与对照组动物相比,对嗜中性粒细胞浸润的抑制增大至79.20%。
雄性Balb/c小鼠中急性香烟烟雾诱导的细胞浸润:用化合物A1和罗氟司特进行如实施例1中所述的针对雄性Balb/c小鼠中急性香烟烟雾诱导的细胞浸润的程序。
结果:结果显示在图10中。
罗氟司特的有效剂量:罗氟司特证明与对照组相比在1、3以及10mg/kg下对巨噬细胞浸润的剂量依赖性抑制。抑制百分比分别为22.2%、51.00%以及69.11%并且50%抑制(ED50)剂量为3.5mg/kg。罗氟司特证明与对照组相比在1、3以及10mg/kg下对嗜中性粒细胞浸润的抑制作用。抑制百分比分别为70.85%、73.69%以及83.01%,并且考虑巨噬细胞浸润的50%抑制剂量(ED50)用于组合研究。
化合物A1的有效剂量:口服施用化合物A1后,与对照组相比在0.1、0.3以及1mg/kg下观察到对巨噬细胞和嗜中性粒细胞浸润的剂量依赖性抑制。巨噬细胞浸润的抑制百分比分别为20.60%、75.19%以及93.11%,并且50%抑制(ED50)剂量为0.20mg/kg。化合物A1证明与对照组相比在0.1、0.3以及1mg/kg下对嗜中性粒细胞浸润的抑制作用。抑制百分比分别为14.76%、51.31%以及112.83%,并且嗜中性粒细胞浸润的50%抑制剂量(ED50)为0.26mg/kg。
各ED50剂量的罗氟司特与化合物A1的组合:与对照组相比,罗氟司特或化合物A1单独在3.5和0.3mg/kg剂量下分别示出对巨噬细胞浸润有26.55%和31.33%的抑制作用。当将罗氟司特(3.5mg/kg)与化合物A1(剂量为0.25mg/kg)相组合时,与对照组动物相比,对巨噬细胞浸润的抑制增大至65.52%。与对照组相比,罗氟司特或化合物A1单独在3.5和0.25mg/kg剂量下分别示出对嗜中性粒细胞浸润有44.42%和36.69%的抑制作用。同样,与对照组相比,罗氟司特(3.5mg/kg)与化合物A1(剂量为0.25mg/kg)的组合示出对嗜中性粒细胞浸润有79.14%的抑制。
虽然已参考特定实施方案描述本文的发明,但应理解这些实施方案仅是说明本发明的原理和应用。因此,应理解在不背离如以上所述的本发明的精神和范围的情况下,可对说明性实施方案进行多种修改,并且可设计其它安排。随附权利要求旨在限定本发明的范围,并且进而将涵盖这些权利要求和其等同物范围内的方法和结构。
本申请中所列举的所有出版物、专利以及专利申请是以引用方式并入本文中,其程度就如同各单独出版物、专利或专利申请被特定且单独地指示以引用方式并入本文中一般。
Claims (34)
1.一种治疗自体免疫、呼吸性和/或炎性疾病或病状的方法,所述方法包括向有需要的受试者施用治疗有效量的(i)PI3K δ抑制剂或双重PI3K δ和γ抑制剂;以及(ii)PDE4抑制剂。
2.根据权利要求1所述的方法,其包括施用PI3K δ抑制剂。
3.根据权利要求1所述的方法,其包括施用双重PI3K δ和γ抑制剂。
4.根据权利要求1至3中任一项所述的方法,其中所述PI3K δ或双重PI3K δ和γ抑制剂为式(I)化合物:
或其互变异构体、其N-氧化物、其药学上可接受的酯、其前药或其药学上可接受的盐,其中:
每次出现的R独立地选自氢、卤素、-ORa、CN、取代的或未取代的C1-6烷基、取代的或未取代的C2-6烯基、取代的或未取代的C2-6炔基、取代的或未取代的C3-8环烷基以及取代的或未取代的杂环基团;
R1和R2可相同或不同并且独立地选自氢、卤素以及取代的或未取代的C1-6烷基,或均直接结合至同一原子的R1和R2可接合以形成氧代基团(=O)或取代的或未取代的、饱和或不饱和的3-10员环(包括R1和R2所结合的碳原子),所述环可任选地包含一个或多个可相同或不同并且选自O、NRa以及S的杂原子;
Cy1为选自以下的单环基团:取代的或未取代的环烷基、取代的或未取代的杂环基团、取代的或未取代的芳基以及取代的或未取代的杂芳基;
Cy2选自取代的或未取代的杂环基团、取代的或未取代的芳基以及取代的或未取代的杂芳基;
L1不存在或选自-(CRaRb)q-、-O-、-S(=O)q-、-NRa-或-C(=Y)-;
每次出现的Ra和Rb可相同或不同并且独立地选自氢、卤素、羟基、氰基、取代的或未取代的(C1-6)烷基、-NRcRd(其中Rc和Rd独立地为氢、卤素、羟基、氰基、取代的或未取代的(C1-6)烷基以及(C1-6)烷氧基)以及-ORc(其中Rc为取代的或未取代的(C1-6)烷基),或当Ra和Rb直接结合至同一原子时,其可接合以形成氧代基团(=O)或形成取代的或未取代的、饱和或不饱和的3-10员环(包括Ra和Rb直接结合的所述同一原子),所述环可任选地包含一个或多个可相同或不同并且选自O、NRd(其中Rd为氢或取代的或未取代的(C1-6)烷基)或S的杂原子;
Y选自O、S以及NRa;
n为1、2、3或4;并且
q为0、1或2。
5.根据权利要求4所述的方法,其中所述PI3K δ或双重PI3K δ和γ抑制剂为式(II)化合物:
或其互变异构体、其N-氧化物、其药学上可接受的酯、其前药或其药学上可接受的盐,其中R、R1、R2、L1、Cy1以及Cy2如权利要求4所定义。
6.根据权利要求4所述的方法,其中所述PI3K δ或双重PI3K δ和γ抑制剂为式(IA-I)、(IA-II)、(IA-III)或(IA-IV)化合物:
或其互变异构体、其N-氧化物、其药学上可接受的酯、其前药或其药学上可接受的盐,其中:
每次出现的X独立地选自CR3或N;并且
每次出现的R3独立地选自氢、羟基、卤素、羧基、氰基、硝基、取代的或未取代的烷基、取代的或未取代的烷氧基、取代的或未取代的烯基、取代的或未取代的炔基、取代的或未取代的芳基、取代的或未取代的芳基烷基、取代的或未取代的环烷基、取代的或未取代的环烷基烷基、取代的或未取代的环烯基烷基、取代的或未取代的环烯基、取代的或未取代的杂芳基、取代的或未取代的杂芳基烷基、取代的或未取代的杂环、取代的杂环基烷基环、取代的或未取代的胍、-COORx、-C(O)Rx、-C(S)Rx、-C(O)NRxRy、-C(O)ONRxRy、-NRyRz、-NRxCONRyRz、-N(Rx)SORy、-N(Rx)SO2Ry、-(=N-N(Rx)Ry)、-NRxC(O)ORy、-NRxRy、-NRxC(O)Ry-、-NRxC(S)Ry、-NRxC(S)NRyRz、-SONRxRy-、-SO2NRxRy-、-ORx、-ORxC(O)NRyRz、-ORxC(O)ORy-、-OC(O)Rx、-OC(O)NRxRy、-RxNRyC(O)Rz、-RxORy、-RxC(O)ORy、-RxC(O)NRyRz、-RxC(O)Rx、-RxOC(O)Ry、-SRx、-SORx、-SO2Rx以及-ONO2,其中以上各基团中的Rx、Ry以及Rz可为氢、取代的或未取代的烷基、取代的或未取代的烷氧基、取代的或未取代的烯基、取代的或未取代的炔基、取代的或未取代的芳基、取代的或未取代的芳基烷基、取代的或未取代的环烷基、取代的或未取代的环烷基烷基、取代的或未取代的环烯基、取代的或未取代的杂芳基、取代的或未取代的杂芳基烷基、取代的或未取代的杂环、取代的或未取代的杂环基烷基环或取代的或未取代的氨基,或Rx、Ry以及Rz中的任意两者可接合以形成取代的或未取代的饱和或不饱和的3-10员环,所述环可任选地包含可相同或不同并且选自O、NRf(其中Rf为氢或取代的或未取代的烷基)或S的杂原子。
7.根据权利要求1、2以及4至6中任一项所述的方法,其中所述PI3K δ抑制剂选自以下各项组成的组:
2-((6-氨基-9H-嘌呤-9-基)甲基)-5-甲基-3-邻甲苯基喹唑啉-4(3H)-酮(IC87114);
(S)-2-(1-((9H-嘌呤-6-基)氨基)丙基)-5-氟-3-苯基喹唑啉-4(3H)-酮(CAL-101);
(S)-2-(1-(9H-嘌呤-6-基氨基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(S)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮,
以及其药学上可接受的盐。
8.根据权利要求1和3至6中任一项所述的方法,其中所述双重PI3K δ和γ抑制剂选自以下各项组成的组:
(S)-3-(1-((9H-嘌呤-6-基)氨基)乙基)-8-氯-2-苯基异喹啉-1(2H)-酮(IPI-145);
(+)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(-)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮,
以及其药学上可接受的盐。
9.根据权利要求1至8中任一项所述的方法,其中所述PDE-4抑制剂选自以下各项组成的组:恩丙茶碱、茶碱、氨茶碱、胆茶碱、阿普司特、罗氟司特、西洛司特、妥非司特、普马芬群、利米司特、阿罗茶碱、阿替唑兰、奥格米坦、D-4418、Bay-198004、BY343、CP-325,366、D-4396(Sch-351591)、AWD-12-281(GW-842470)、NCS-613、CDP-840、D-4418、PD-168787、T-440、T-2585、V 1 1294A、CI-1018、CDC-801、CDC-3052、D-22888、YM-58997、Z-15370、N-(3,5-二氯-1-氧代-吡啶-4-基)-4-二氟甲氧基-3-环丙基甲氧基苯甲酰胺、(-)-p-[(4aR*,10bS*)-9-乙氧基-1,2,3,4,4a,10b-六氢-8-甲氧基-2-甲基苯并[s][1,6]-二氮杂萘-6-基]-N,N-二异丙基苯甲酰胺、(R)-(+)-1-(4-溴苄基)-4-[(3-环戊氧基)-4-甲氧基苯基]-2-吡咯烷酮、3-(环戊氧基-4-甲氧基苯基)-1-(4-N′-[N-2-氰基-S-甲基-异硫代脲基]苄基)-2-吡咯烷酮、顺[4-氰基-4-(3-环戊氧基-4-甲氧基苯基)环己烷-1-羧酸]、2-甲酯基-4-氰基-4-(3-环丙基甲氧基-4-二氟甲氧基苯基)环己烷-1-酮、顺[4-氰基-4-(3-环丙基甲氧基-4-二氟甲氧基苯基)环己烷-1-醇]、乙酸(R)-(+)-乙基[4-(3-环戊氧基-4-甲氧基苯基)吡咯烷-2-亚基]酯、乙酸(S)-(-)-乙基[4-(3-环戊氧基-4-甲氧基苯基)吡咯烷-2-亚基]酯、9环戊基-5,6-二氢-7-乙基-3-(2-噻吩基)-9H-吡唑并[3,4c]-1,2,4-三唑并[4,3a]吡啶以及9-环戊基-5,6-二氢-7-乙基-3-(叔丁基)-9H-吡唑并[3,4c]-1,2,4-三唑并[4,3a]吡啶,以及其药学上可接受的盐。
10.根据权利要求1至9中任一项所述的方法,其中所述PDE-4抑制剂选自以下各项组成的组:茶碱、氨茶碱、胆茶碱、罗氟司特、阿普司特以及其药学上可接受的盐。
11.根据权利要求1至10中任一项所述的方法,其中作为组合制剂同时施用所述治疗有效量的所述PI3K δ或双重PI3K δ和γ抑制剂以及所述治疗有效量的PDE4抑制剂。
12.根据权利要求1至11中任一项所述的方法,其中顺序施用所述治疗有效量的PI3K δ或双重PI3K δ和γ抑制剂以及所述治疗有效量的PDE4抑制剂。
13.根据权利要求12所述的方法,其中在所述治疗有效量的PI3Kδ或双重PI3K δ和γ抑制剂之前施用所述治疗有效量的PDE-4抑制剂。
14.根据权利要求1至13中任一项所述的方法,其中所述治疗有效量的PI3K δ或双重PI3K δ和γ抑制剂是每天两次至每三周一次进行施用,并且所述治疗有效量的所述PDE4抑制剂是每天两次至每三周一次进行施用。
15.根据权利要求1至14中任一项所述的方法,其中所述自体免疫、呼吸性和/或炎性疾病或病状选自以下各项组成的组:哮喘、慢性阻塞性肺病、类风湿性关节炎、炎性肠病、肾小球性肾炎、神经炎性疾病、多发性硬化症、葡萄膜炎、牛皮癣、关节炎、血管炎、皮炎、骨关节炎、炎性肌病、过敏性鼻炎、阴道炎、间质性膀胱炎、硬皮病、骨质疏松症、湿疹、同种异体移植或异种移植(器官、骨髓、干细胞以及其它细胞和组织)移植物排斥反应、移植物对抗宿主疾病、红斑狼疮、炎性疾病、I型糖尿病、肺纤维化、皮肌炎、舍格伦氏综合症、甲状腺炎、重症肌无力、自体免疫溶血性贫血、囊肿性纤维化、慢性复发性肝炎、原发性胆汁性肝硬变、过敏性结膜炎、特异性皮炎以及其组合。
16.根据权利要求1至14中任一项所述的方法,其中所述自体免疫、呼吸性和/或炎性疾病或病状选自以下各项组成的组:哮喘、过敏性鼻炎、非过敏性鼻炎、类风湿性关节炎、慢性阻塞性肺病以及特异性皮炎。
17.根据权利要求1至16中任一项所述的方法,其中所述PI3K δ或双重PI3K δ和γ抑制剂以及所述PDE4抑制剂各自按范围为约0.01mg至约1000mg的量施用。
18.根据权利要求1至17中任一项所述的方法,其中所述PI3K δ或双重PI3K δ和γ抑制剂以及所述PDE4抑制剂以按重量计约1∶100至约100∶1的比率施用。
19.一种药物组合物,其包含(i)PI3K δ或双重PI3K δ和γ抑制剂或其药学上可接受的盐;(ii)PDE4抑制剂;以及(iii)任选地药学上可接受的载体、助流剂、稀释剂或赋形剂。
20.根据权利要求19所述的药物组合物,其中所述PI3K δ或双重PI3K δ和γ抑制剂为式(I)化合物:
或其互变异构体、其N-氧化物、其药学上可接受的酯、其前药或其药学上可接受的盐,其中:
每次出现的R独立地选自氢、卤素、-ORa、CN、取代的或未取代的C1-6烷基、取代的或未取代的C2-6烯基、取代的或未取代的C2-6炔基、取代的或未取代的C3-8环烷基以及取代的或未取代的杂环基团;
R1和R2可相同或不同并且独立地选自氢、卤素以及取代的或未取代的C1-6烷基,或均直接结合至同一原子的R1和R2可接合以形成氧代基团(=O)或取代的或未取代的、饱和或不饱和的3-10员环(包括R1和R2所结合的碳原子),所述环可任选地包含一个或多个可相同或不同并且选自O、NRa以及S的杂原子;
Cy1为选自以下的单环基团:取代的或未取代的环烷基、取代的或未取代的杂环基团、取代的或未取代的芳基以及取代的或未取代的杂芳基;
Cy2选自取代的或未取代的杂环基团、取代的或未取代的芳基以及取代的或未取代的杂芳基;
L1不存在或选自-(CRaRb)q-、-O-、-S(=O)q-、-NRa-或-C(=Y)-;
每次出现的Ra和Rb可相同或不同并且独立地选自氢、卤素、羟基、氰基、取代的或未取代的(C1-6)烷基、-NRcRd(其中Rc和Rd独立地为氢、卤素、羟基、氰基、取代的或未取代的(C1-6)烷基以及(C1-6)烷氧基)以及-ORc(其中Rc为取代的或未取代的(C1-6)烷基),或当Ra和Rb直接结合至同一原子时,其可接合以形成氧代基团(=O)或形成取代的或未取代的、饱和或不饱和的3-10员环(包括Ra和Rb直接结合的所述同一原子),所述环可任选地包含一个或多个可相同或不同并且选自O、NRd(其中Rd为氢或取代的或未取代的(C1-6)烷基)或S的杂原子;
Y选自O、S以及NRa;
n为1、2、3或4;并且
q为0、1或2。
21.根据权利要求20所述的药物组合物,其中所述式(I)化合物为式(II)化合物:
或其互变异构体、其N-氧化物、其药学上可接受的酯、其前药或其药学上可接受的盐,其中R、R1、R2、L1、Cy1以及Cy2如权利要求20所定义。
22.根据权利要求20所述的药物组合物,其中所述式(I)化合物为式(IA-I)、(IA-II)、(IA-III)或(IA-IV)化合物:
或其互变异构体、其N-氧化物、其药学上可接受的酯、其前药或其药学上可接受的盐,其中:
每次出现的X独立地选自CR3或N;并且
每次出现的R3独立地选自氢、羟基、卤素、羧基、氰基、硝基、取代的或未取代的烷基、取代的或未取代的烷氧基、取代的或未取代的烯基、取代的或未取代的炔基、取代的或未取代的芳基、取代的或未取代的芳基烷基、取代的或未取代的环烷基、取代的或未取代的环烷基烷基、取代的或未取代的环烯基烷基、取代的或未取代的环烯基、取代的或未取代的杂芳基、取代的或未取代的杂芳基烷基、取代的或未取代的杂环、取代的杂环基烷基环、取代的或未取代的胍、-COORx、-C(O)Rx、-C(S)Rx、-C(O)NRxRy、-C(O)ONRxRy、-NRyRz、-NRxCONRyRz、-N(Rx)SORy、-N(Rx)SO2Ry、-(=N-N(Rx)Ry)、-NRxC(O)ORy、-NRxRy、-NRxC(O)Ry-、-NRxC(S)Ry、-NRxC(S)NRyRz、-SONRxRy-、-SO2NRxRy-、-ORx、-ORxC(O)NRyRz、-ORxC(O)ORy-、-OC(O)Rx、-OC(O)NRxRy、-RxNRyC(O)Rz、-RxORy、-RxC(O)ORy、-RxC(O)NRyRz、-RxC(O)Rx、-RxOC(O)Ry、-SRx、-SORx、-SO2Rx以及-ONO2,其中以上各基团中的Rx、Ry以及Rz可为氢、取代的或未取代的烷基、取代的或未取代的烷氧基、取代的或未取代的烯基、取代的或未取代的炔基、取代的或未取代的芳基、取代的或未取代的芳基烷基、取代的或未取代的环烷基、取代的或未取代的环烷基烷基、取代的或未取代的环烯基、取代的或未取代的杂芳基、取代的或未取代的杂芳基烷基、取代的或未取代的杂环、取代的或未取代的杂环基烷基环或取代的或未取代的氨基,或Rx、Ry以及Rz中的任意两者可接合以形成取代的或未取代的饱和或不饱和的3-10员环,所述环可任选地包含可相同或不同并且选自O、NRf(其中Rf为氢或取代的或未取代的烷基)或S的杂原子。
23.根据权利要求19所述的药物组合物,其中所述PI3K δ抑制剂选自以下各项组成的组:
2-((6-氨基-9H-嘌呤-9-基)甲基)-5-甲基-3-邻甲苯基喹唑啉-4(3H)-酮(IC87114);
(S)-2-(1-((9H-嘌呤-6-基)氨基)丙基)-5-氟-3-苯基喹唑啉-4(3H)-酮(CAL-101);
(S)-2-(1-(9H-嘌呤-6-基氨基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(S)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮,
以及其药学上可接受的盐。
24.根据权利要求19所述的药物组合物,其中所述双重PI3K δ和γ抑制剂选自以下各项组成的组:
(S)-3-(1-((9H-嘌呤-6-基)氨基)乙基)-8-氯-2-苯基异喹啉-1(2H)-酮(IPI-145);
(+)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(-)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮,
以及其药学上可接受的盐。
25.根据权利要求19至24中任一项所述的药物组合物,其中所述PDE-4抑制剂选自以下各项组成的组:恩丙茶碱、茶碱、氨茶碱、胆茶碱、阿普司特、罗氟司特、西洛司特、妥非司特、普马芬群、利米司特、阿罗茶碱、阿替唑兰、奥格米坦、D-4418、Bay-198004、BY343、CP-325,366、D-4396(Sch-351591)、AWD-12-281(GW-842470)、NCS-613、CDP-840、D-4418、PD-168787、T-440、T-2585、V 11294A、CI-1018、CDC-801、CDC-3052、D-22888、YM-58997、Z-15370、N-(3,5-二氯-1-氧代-吡啶-4-基)-4-二氟甲氧基-3-环丙基甲氧基苯甲酰胺、(-)-p-[(4aR*,10bS*)-9-乙氧基-1,2,3,4,4a,10b-六氢-8-甲氧基-2-甲基苯并[s][1,6]-二氮杂萘-6-基]-N,N-二异丙基苯甲酰胺、(R)-(+)-1-(4-溴苄基)-4-[(3-环戊氧基)-4-甲氧基苯基]-2-吡咯烷酮、3-(环戊氧基-4-甲氧基苯基)-1-(4-N′-[N-2-氰基-S-甲基-异硫代脲基]苄基)-2-吡咯烷酮、顺[4-氰基-4-(3-环戊氧基-4-甲氧基苯基)环己烷-1-羧酸]、2-甲酯基-4-氰基-4-(3-环丙基甲氧基-4-二氟甲氧基苯基)环己烷-1-酮、顺[4-氰基-4-(3-环丙基甲氧基-4-二氟甲氧基苯基)环己烷-1-醇]、乙酸(R)-(+)-乙基[4-(3-环戊氧基-4-甲氧基苯基)吡咯烷-2-亚基]酯、乙酸(S)-(-)-乙基[4-(3-环戊氧基-4-甲氧基苯基)吡咯烷-2-亚基]酯、9环戊基-5,6-二氢-7-乙基-3-(2-噻吩基)-9H-吡唑并[3,4c]-1,2,4-三唑并[4,3a]吡啶以及9-环戊基-5,6-二氢-7-乙基-3-(叔丁基)-9H-吡唑并[3,4c]-1,2,4-三唑并[4,3a]吡啶,以及其药学上可接受的盐。
26.根据权利要求19至25中任一项所述的方法,其中所述PDE-4抑制剂选自以下各项组成的组:茶碱、氨茶碱、胆茶碱、罗氟司特和阿普司特以及药学上可接受的盐。
27.根据权利要求19至26中任一项所述的药物组合物,其中所述组合物包含0.01mg至约1000mg的所述PI3K δ或双重PI3K δ和γ抑制剂以及0.01mg至约1000mg的所述PDE4抑制剂。
28.根据权利要求19至27中任一项所述的药物组合物,其用于治疗以下疾病的方法中:自体免疫、呼吸性和/或炎性疾病或病状,所述疾病或病状选自以下各项组成的组:哮喘、慢性阻塞性肺病、类风湿性关节炎、炎性肠病、肾小球性肾炎、神经炎性疾病、多发性硬化症、葡萄膜炎、牛皮癣、关节炎、血管炎、皮炎、骨关节炎、炎性肌病、过敏性鼻炎、阴道炎、间质性膀胱炎、硬皮病、骨质疏松症、湿疹、同种异体移植或异种移植(器官、骨髓、干细胞以及其它细胞和组织)移植物排斥反应、移植物对抗宿主疾病、红斑狼疮、炎性疾病、I型糖尿病、肺纤维化、皮肌炎、舍格伦氏综合症、甲状腺炎(桥本氏甲状腺炎和自体免疫甲状腺炎)、重症肌无力、自体免疫溶血性贫血、囊肿性纤维化、慢性复发性肝炎、原发性胆汁性肝硬变、过敏性结膜炎和特异性皮炎以及其组合。
29.根据权利要求19至28中任一项所述的药物组合物的用途,其用于制造供治疗以下疾病的药剂:自体免疫、呼吸性以及炎性疾病和病状,所述疾病和病状选自哮喘、慢性阻塞性肺病、类风湿性关节炎、炎性肠病、肾小球性肾炎、神经炎性疾病、多发性硬化症、葡萄膜炎、牛皮癣、关节炎、血管炎、皮炎、骨关节炎、炎性肌病、过敏性鼻炎、阴道炎、间质性膀胱炎、硬皮病、骨质疏松症、湿疹、同种异体移植或异种移植(器官、骨髓、干细胞以及其它细胞和组织)移植物排斥反应、移植物对抗宿主疾病、红斑狼疮、炎性疾病、I型糖尿病、肺纤维化、皮肌炎、舍格伦氏综合症、甲状腺炎(桥本氏甲状腺炎和自体免疫甲状腺炎)、重症肌无力、自体免疫溶血性贫血、囊肿性纤维化、慢性复发性肝炎、原发性胆汁性肝硬变、过敏性结膜炎和特异性皮炎以及其组合。
30.一种用于治疗自体免疫、呼吸性或炎性疾病或病状的试剂盒,所述试剂盒包括:
(i)PI3K δ或PI3K δ和γ抑制剂;以及(ii)PDE4抑制剂,其处于单一药物组合物或单独的药物组合物中;
(ii)任选地,用于使用所述PI3K δ或PI3K δ和γ抑制剂以及PDE4抑制剂治疗自体免疫、呼吸性或炎性疾病或病状的用法说明书;以及
(iii)任选地,用于放置所述一种或多种药物组合物的容器。
31.根据权利要求30所述的试剂盒,其中所述PI3K δ或双重PI3Kδ和γ抑制剂以及PDE4抑制剂是用于治疗自体免疫、呼吸性或炎性疾病或病状,所述疾病或病状选自哮喘、慢性阻塞性肺病、类风湿性关节炎、炎性肠病、肾小球性肾炎、神经炎性疾病、多发性硬化症、葡萄膜炎、牛皮癣、关节炎、血管炎、皮炎、骨关节炎、炎性肌病、过敏性鼻炎、阴道炎、间质性膀胱炎、硬皮病、骨质疏松症、湿疹、同种异体移植或异种移植(器官、骨髓、干细胞以及其它细胞和组织)移植物排斥反应、移植物对抗宿主疾病、红斑狼疮、炎性疾病、I型糖尿病、肺纤维化、皮肌炎、舍格伦氏综合症、甲状腺炎(桥本氏甲状腺炎和自体免疫甲状腺炎)、重症肌无力、自体免疫溶血性贫血、囊肿性纤维化、慢性复发性肝炎、原发性胆汁性肝硬变、过敏性结膜炎和特异性皮炎。
32.根据权利要求30或31所述的试剂盒,其中所述PI3K δ或双重PI3K δ和γ抑制剂选自式(I)、(II)、(IA-I)、(IA-II)、(IA-III)以及(IA-IV)的化合物。
33.根据权利要求30或31所述的试剂盒,其中所述PI3K δ抑制剂选自:
2-((6-氨基-9H-嘌呤-9-基)甲基)-5-甲基-3-邻甲苯基喹唑啉-4(3H)-酮(IC87114);
(S)-2-(1-((9H-嘌呤-6-基)氨基)丙基)-5-氟-3-苯基喹唑啉-4(3H)-酮(CAL-101);
(S)-2-(1-(9H-嘌呤-6-基氨基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(S)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-6-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮,
以及其药学上可接受的盐。
34.根据权利要求30或31所述的试剂盒,其中所述双重PI3K δ和γ抑制剂选自:
(S)-3-(1-((9H-嘌呤-6-基)氨基)乙基)-8-氯-2-苯基异喹啉-1(2H)-酮(IPI-145);
(+)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮;
(-)-2-(1-(4-氨基-3-(3-氟-4-异丙氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)乙基)-5-氟-3-(3-氟苯基)-4H-苯并吡喃-4-酮,
以及其药学上可接受的盐。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010719781.5A CN111904962A (zh) | 2012-11-08 | 2013-11-07 | 含有PDE4抑制剂和PI3 δ或双重PI3 δ-γ激酶抑制剂的药物组合物 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2762CH2012 | 2012-11-08 | ||
IN4688/CHE/2012 | 2012-11-08 | ||
IN2762/CHE/2012 | 2012-11-08 | ||
IN4688CH2012 | 2012-11-08 | ||
PCT/IB2013/059983 WO2014072937A1 (en) | 2012-11-08 | 2013-11-07 | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010719781.5A Division CN111904962A (zh) | 2012-11-08 | 2013-11-07 | 含有PDE4抑制剂和PI3 δ或双重PI3 δ-γ激酶抑制剂的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104870017A true CN104870017A (zh) | 2015-08-26 |
CN104870017B CN104870017B (zh) | 2020-08-14 |
Family
ID=54188815
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010719781.5A Pending CN111904962A (zh) | 2012-11-08 | 2013-11-07 | 含有PDE4抑制剂和PI3 δ或双重PI3 δ-γ激酶抑制剂的药物组合物 |
CN201380063816.2A Expired - Fee Related CN104870017B (zh) | 2012-11-08 | 2013-11-07 | 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010719781.5A Pending CN111904962A (zh) | 2012-11-08 | 2013-11-07 | 含有PDE4抑制剂和PI3 δ或双重PI3 δ-γ激酶抑制剂的药物组合物 |
Country Status (9)
Country | Link |
---|---|
US (4) | US9737521B2 (zh) |
EP (1) | EP2916868B1 (zh) |
JP (2) | JP6434416B2 (zh) |
KR (2) | KR20210010958A (zh) |
CN (2) | CN111904962A (zh) |
CA (1) | CA2889905A1 (zh) |
EA (1) | EA035391B1 (zh) |
HK (1) | HK1214159A1 (zh) |
WO (1) | WO2014072937A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113332439A (zh) * | 2014-09-03 | 2021-09-03 | 理森制药股份公司 | 包含双重PI3Kδ-γ激酶抑制剂和皮质类固醇的治疗方法及组合物 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009088990A1 (en) | 2008-01-04 | 2009-07-16 | Intellikine, Inc. | Certain chemical entities, compositions and methods |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
JP5889795B2 (ja) | 2009-11-05 | 2016-03-22 | ライゼン・ファーマシューティカルズ・エスアー | 新規キナーゼモジュレーター |
NZ612909A (en) | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
PT2705029T (pt) * | 2011-05-04 | 2019-02-01 | Rhizen Pharmaceuticals S A | Novos compostos como moduladores de proteína quinases |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
AU2013343291B2 (en) | 2012-11-07 | 2018-05-10 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors and their use in therapy |
US9737521B2 (en) * | 2012-11-08 | 2017-08-22 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor |
CN105358550B (zh) | 2013-05-10 | 2018-04-06 | 卡鲁斯治疗有限公司 | 组蛋白脱乙酰基酶抑制剂 |
US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
CN105548393A (zh) * | 2015-12-14 | 2016-05-04 | 成都百裕制药股份有限公司 | 一种检测阿普斯特原料中杂质含量的方法 |
HUE063428T2 (hu) | 2016-01-11 | 2024-01-28 | Univ London Queen Mary | PI3K P-DELTA 110 gátlószerei rák kezelésében vírusok bejuttatására történõ alkalmazásra |
GB201602527D0 (en) * | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
CN109640999A (zh) | 2016-06-24 | 2019-04-16 | 无限药品股份有限公司 | 组合疗法 |
EP3412294A1 (en) * | 2017-06-08 | 2018-12-12 | Universite De Fribourg | Hdac1/2 activator for promoting and/or accelerating myelination and/or remyelination |
US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
EP3883634A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
US20220168297A1 (en) * | 2020-12-01 | 2022-06-02 | Reverspah Llc | Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension |
TW202241494A (zh) * | 2021-02-10 | 2022-11-01 | 大陸商同潤生物醫藥(上海)有限公司 | 治療腫瘤的方法和組合 |
IL311534A (en) * | 2021-09-22 | 2024-05-01 | Iolyx Therapeutics Inc | Methods for treating ocular inflammatory diseases |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011055215A2 (en) * | 2009-11-05 | 2011-05-12 | Incozen Therapeutics Pvt. Ltd. | Novel kinase modulators |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60144277D1 (de) | 2000-04-25 | 2011-05-05 | Icos Corp | Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
NZ537308A (en) * | 2002-05-28 | 2009-09-25 | Nycomed Gmbh | Ophthalmological use of roflumilast for the treatment of diseases of the eye |
CN101031569B (zh) * | 2004-05-13 | 2011-06-22 | 艾科斯有限公司 | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 |
EA012178B1 (ru) | 2004-09-03 | 2009-08-28 | Лаборатуар Сероно Са | Пиридинметиленазолидиноны и их применение |
ES2446417T3 (es) | 2007-03-23 | 2014-03-07 | Amgen Inc. | Derivados de quinolina o quinoxalina sustituidos en 3 y su uso como inhibidores de fosfatidilinositol 3-cinasa (PI3K) |
CA2680783C (en) | 2007-03-23 | 2012-04-24 | Amgen Inc. | Heterocyclic compounds and their uses |
AR067562A1 (es) | 2007-07-18 | 2009-10-14 | Novartis Ag | Compuestos heterociclicos inhibidores de kinasa |
EP2220089A4 (en) | 2007-11-13 | 2011-10-26 | Icos Corp | HEMMER OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE-DELTA |
WO2009088990A1 (en) | 2008-01-04 | 2009-07-16 | Intellikine, Inc. | Certain chemical entities, compositions and methods |
US8193182B2 (en) * | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
ES2526966T3 (es) | 2008-06-05 | 2015-01-19 | Glaxo Group Limited | Compuestos novedosos |
US8513221B2 (en) | 2008-07-07 | 2013-08-20 | Xcovery Holding, LLC | PI3K isoform selective inhibitors |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
ES2539478T3 (es) | 2008-11-11 | 2015-07-01 | Xcovery Holding Company Llc | Inhibidores de PI3K/mTOR cinasa |
AU2009313878B2 (en) | 2008-11-13 | 2016-01-07 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
WO2010092015A1 (en) | 2009-02-10 | 2010-08-19 | Cellzome Limited | Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors |
CN102317282A (zh) | 2009-02-12 | 2012-01-11 | 安斯泰来制药有限公司 | 杂环衍生物 |
EP2398810A1 (en) | 2009-02-17 | 2011-12-28 | Vertex Pharmaceuticals Incorporated | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase |
WO2010135014A1 (en) | 2009-02-27 | 2010-11-25 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドGlaxo Group Limited | Pi3キナーゼの阻害剤としての4−オキサジアゾール−2−イル−インダゾール |
BRPI1012333A2 (pt) * | 2009-03-24 | 2016-03-29 | Gilead Calistoga Llc | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso |
WO2010110686A1 (en) | 2009-03-27 | 2010-09-30 | Pathway Therapeutics Limited | Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy |
US8461158B2 (en) | 2009-03-27 | 2013-06-11 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
US8546409B2 (en) | 2009-04-20 | 2013-10-01 | Gilead Calistoga Llc | Methods of treatment for solid tumors |
CA2772371A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
US8173650B2 (en) | 2009-05-27 | 2012-05-08 | Genentech, Inc. | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use |
EP2440556A1 (en) | 2009-06-10 | 2012-04-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase |
EP2445902A2 (en) | 2009-06-25 | 2012-05-02 | Amgen, Inc | Heterocyclic compounds and their uses as inhibitors of pi3k activity |
CA2765823A1 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Tricyclic heterocyclic compounds as mediators of p13k activity |
WO2010151740A2 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Heterocyclic compounds and their uses |
NZ597050A (en) | 2009-06-29 | 2014-02-28 | Incyte Corp | Pyrimidinones as pi3k inhibitors |
TW201105662A (en) | 2009-07-07 | 2011-02-16 | Pathway Therapeutics Ltd | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
CN102647987A (zh) | 2009-07-21 | 2012-08-22 | 吉里德卡利斯托加公司 | 使用pi3k抑制剂治疗肝脏障碍 |
US8981087B2 (en) | 2009-07-29 | 2015-03-17 | Karus Therapeutics Limited | Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors |
JP5819831B2 (ja) | 2009-08-17 | 2015-11-24 | インテリカイン, エルエルシー | 複素環式化合物およびそれらの使用 |
JP5746172B2 (ja) | 2009-08-20 | 2015-07-08 | カルス セラピューティクス リミテッド | ホスホイノシチド3−キナーゼ阻害剤としての三環式複素環化合物 |
CA2775942A1 (en) | 2009-09-29 | 2011-04-07 | Xcovery Holding Company Llc | Pi3k (delta) selective inhibitors |
US20110081316A1 (en) | 2009-10-02 | 2011-04-07 | Vertex Pharmaceuticals Incorporated | Pyrazole inhibitors of phosphatidylinositol 3-kinase |
GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
EP2492269A4 (en) | 2009-10-19 | 2013-08-07 | Taisho Pharmaceutical Co Ltd | aminothiazole |
US8863839B2 (en) | 2009-12-17 | 2014-10-21 | Exxonmobil Upstream Research Company | Enhanced convection for in situ pyrolysis of organic-rich rock formations |
US8680108B2 (en) | 2009-12-18 | 2014-03-25 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
JP5770751B2 (ja) | 2010-02-22 | 2015-08-26 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ピリド[3,2−d]ピリミジン系のPI3Kデルタ阻害化合物および使用方法 |
UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
EP2579878A1 (en) | 2010-06-11 | 2013-04-17 | Gilead Calistoga LLC | Methods of treating hematological disorders with quinazolinone compounds in selected patients |
WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
AU2011272862A1 (en) | 2010-06-30 | 2013-01-10 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of PI3K activity |
WO2012003264A1 (en) | 2010-06-30 | 2012-01-05 | Amgen Inc. | Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors |
WO2012003278A1 (en) | 2010-06-30 | 2012-01-05 | Amgen Inc. | Quinolines as p13k inhibitors |
EP2588467A1 (en) | 2010-07-01 | 2013-05-08 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
EP2588468B1 (en) | 2010-07-01 | 2014-03-26 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
MX2012015134A (es) | 2010-07-02 | 2013-05-06 | Amgen Inc | Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k. |
UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
ES2536780T3 (es) | 2010-07-14 | 2015-05-28 | F. Hoffmann-La Roche Ag | Compuestos de purina selectivos para I3 p110 delta, y métodos de uso |
EP2598145A1 (en) | 2010-07-28 | 2013-06-05 | Boehringer Ingelheim International GmbH | Pharmaceutical composition for treatment of respiratory and inflammatory diseases |
DE102010032813A1 (de) | 2010-07-30 | 2012-02-02 | Osram Opto Semiconductors Gmbh | Verfahren zur Herstellung eines optoelektronischen Halbleiterbauteils und optoelektronisches Halbleiterbauteil |
PT2600830T (pt) | 2010-08-03 | 2018-04-02 | Chiesi Farm Spa | Formulação de pó seco que compreende um inibidor de fosfodiesterase |
RU2578975C2 (ru) | 2010-08-03 | 2016-03-27 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы |
CA2808435C (en) | 2010-08-10 | 2017-05-09 | Astellas Pharma Inc. | Heterocyclic compound |
TW201217365A (en) | 2010-08-11 | 2012-05-01 | Millennium Pharm Inc | Heteroaryls and uses thereof |
HUE026059T2 (en) | 2010-09-08 | 2016-05-30 | Glaxosmithkline Ip Dev Ltd | N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazol-6-yl ] Polymorphs and salts of 2 - (methyloxy) -3-pyridinyl] methanesulfonamide |
EP2616442B8 (en) | 2010-09-14 | 2018-10-17 | Exelixis, Inc. | Inhibitors of pi3k-delta and methods of their use and manufacture |
TWI617560B (zh) | 2010-09-14 | 2018-03-11 | 伊塞利克斯公司 | PI3Kδ 抑制劑以及其應用和生產方法 |
EP2619209A1 (en) | 2010-09-24 | 2013-07-31 | Gilead Calistoga LLC | Atropisomers of pi3k-inhibiting compounds |
WO2012044641A1 (en) | 2010-09-29 | 2012-04-05 | Pathway Therapeutics Inc. | 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
US20140031355A1 (en) | 2010-11-04 | 2014-01-30 | Amgen Inc. | Heterocyclic compounds and their uses |
EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
CA2816144A1 (en) | 2010-11-17 | 2012-05-24 | Amgen Inc. | Quinoline derivatives as pik3 inhibitors |
AR084366A1 (es) | 2010-12-20 | 2013-05-08 | Incyte Corp | N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k |
CA2822590A1 (en) | 2010-12-23 | 2012-06-28 | Amgen Inc. | Heterocyclic compounds and their uses |
NZ612909A (en) | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
WO2012107465A1 (en) | 2011-02-09 | 2012-08-16 | F. Hoffmann-La Roche Ag | Heterocyclic compounds as pi3 kinase inhibitors |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
ES2533042T3 (es) | 2011-02-25 | 2015-04-07 | Takeda Pharmaceutical Company Limited | Oxazinopteridinas y oxazinopteridinonas N-sustituidas |
US20140213630A1 (en) | 2011-03-08 | 2014-07-31 | Thomas Diacovo | Methods and pharmaceutical compositions for treating lymphoid malignancy |
SG10201601909TA (en) | 2011-03-11 | 2016-04-28 | Gilead Calistoga Llc | Combination Therapies For Hematologic Malignancies |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
US8664230B2 (en) | 2011-03-17 | 2014-03-04 | The Asan Foundation | Pyridopyrimidine derivatives and use thereof |
MX340013B (es) | 2011-03-21 | 2016-06-22 | Hoffmann La Roche | Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso. |
SG193982A1 (en) | 2011-03-28 | 2013-11-29 | Mei Pharma Inc | (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases |
WO2012135175A1 (en) | 2011-03-28 | 2012-10-04 | Pathway Therapeutics Inc. | (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
WO2012135166A1 (en) | 2011-03-28 | 2012-10-04 | Pathway Therapeutics Inc. | (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases |
US8530470B2 (en) | 2011-04-13 | 2013-09-10 | Astrazeneca Ab | Chromenone derivatives |
EP2518070A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
EP2518071A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
PT2705029T (pt) | 2011-05-04 | 2019-02-01 | Rhizen Pharmaceuticals S A | Novos compostos como moduladores de proteína quinases |
TWI565709B (zh) | 2011-07-19 | 2017-01-11 | 英菲尼提製藥股份有限公司 | 雜環化合物及其用途 |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8642844B2 (en) | 2011-08-23 | 2014-02-04 | Monsanto Technology Llc | Soybean variety D2011905 |
AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
BR122019020716B1 (pt) | 2011-09-02 | 2021-02-17 | Incyte Holdings Corporation | heterociclilaminas como inibidores de pi3k e composição farmacêutica que as compreende |
US20140235643A1 (en) | 2011-10-04 | 2014-08-21 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
CN103987699A (zh) | 2011-10-21 | 2014-08-13 | 诺华股份有限公司 | 作为pi3k调节剂的喹唑啉衍生物 |
WO2013067141A1 (en) | 2011-11-01 | 2013-05-10 | Exelixis, Inc. | N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies |
WO2013067306A1 (en) | 2011-11-02 | 2013-05-10 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers |
US9682141B2 (en) | 2011-11-11 | 2017-06-20 | Intellikine Llc | Combination of kinase inhibitors and uses thereof |
EP2782571A4 (en) | 2011-11-23 | 2015-04-01 | Intellikine Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
WO2013082540A1 (en) | 2011-12-02 | 2013-06-06 | Gilead Calistoga Llc | Compositions and methods of treating a proliferative disease with a quinazolinone derivative |
WO2013090725A1 (en) | 2011-12-15 | 2013-06-20 | Philadelphia Health & Education Corporation | NOVEL PI3K p110 INHIBITORS AND METHODS OF USE THEREOF |
WO2013116562A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
BR112014021935A2 (pt) | 2012-03-05 | 2019-09-24 | Gilead Calistoga Llc | formas polimórficas de (s)-2(l-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolina-4(3h)ona |
GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
TWI586378B (zh) | 2012-03-13 | 2017-06-11 | 瑞斯比維特有限公司 | 新穎醫藥調配物 |
US9737521B2 (en) | 2012-11-08 | 2017-08-22 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor |
-
2013
- 2013-11-07 US US14/441,758 patent/US9737521B2/en active Active
- 2013-11-07 CN CN202010719781.5A patent/CN111904962A/zh active Pending
- 2013-11-07 CN CN201380063816.2A patent/CN104870017B/zh not_active Expired - Fee Related
- 2013-11-07 CA CA2889905A patent/CA2889905A1/en not_active Abandoned
- 2013-11-07 WO PCT/IB2013/059983 patent/WO2014072937A1/en active Application Filing
- 2013-11-07 EP EP13795866.6A patent/EP2916868B1/en active Active
- 2013-11-07 JP JP2015541279A patent/JP6434416B2/ja not_active Expired - Fee Related
- 2013-11-07 KR KR1020217001956A patent/KR20210010958A/ko not_active Application Discontinuation
- 2013-11-07 EA EA201590721A patent/EA035391B1/ru unknown
- 2013-11-07 KR KR1020157013518A patent/KR20150079745A/ko active Application Filing
-
2016
- 2016-02-26 HK HK16102228.2A patent/HK1214159A1/zh unknown
-
2017
- 2017-07-19 US US15/654,181 patent/US10058539B2/en active Active
-
2018
- 2018-06-20 US US16/013,607 patent/US10413532B2/en not_active Expired - Fee Related
- 2018-08-29 JP JP2018160208A patent/JP7030656B2/ja active Active
-
2019
- 2019-08-30 US US16/557,025 patent/US11065236B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011055215A2 (en) * | 2009-11-05 | 2011-05-12 | Incozen Therapeutics Pvt. Ltd. | Novel kinase modulators |
Non-Patent Citations (1)
Title |
---|
ARMIN HATZELMANN ETAL: "Anti-Inflammatory and Immunomodulatory Potential of the Novel PED4 Inhibitor Roflumilast in Vitro", 《THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113332439A (zh) * | 2014-09-03 | 2021-09-03 | 理森制药股份公司 | 包含双重PI3Kδ-γ激酶抑制剂和皮质类固醇的治疗方法及组合物 |
Also Published As
Publication number | Publication date |
---|---|
CA2889905A1 (en) | 2014-05-15 |
HK1214159A1 (zh) | 2016-07-22 |
CN104870017B (zh) | 2020-08-14 |
JP6434416B2 (ja) | 2018-12-05 |
US10058539B2 (en) | 2018-08-28 |
WO2014072937A1 (en) | 2014-05-15 |
US9737521B2 (en) | 2017-08-22 |
JP2015536973A (ja) | 2015-12-24 |
US20190083475A1 (en) | 2019-03-21 |
US20200237735A1 (en) | 2020-07-30 |
KR20150079745A (ko) | 2015-07-08 |
JP7030656B2 (ja) | 2022-03-07 |
EP2916868B1 (en) | 2022-05-11 |
US10413532B2 (en) | 2019-09-17 |
CN111904962A (zh) | 2020-11-10 |
US20150272936A1 (en) | 2015-10-01 |
JP2018203760A (ja) | 2018-12-27 |
EP2916868A1 (en) | 2015-09-16 |
EA035391B1 (ru) | 2020-06-05 |
KR20210010958A (ko) | 2021-01-28 |
US20170319558A1 (en) | 2017-11-09 |
EA201590721A1 (ru) | 2015-09-30 |
US11065236B2 (en) | 2021-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104870017A (zh) | 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物 | |
KR101607081B1 (ko) | 디피피-4 저해약과 다른 당뇨병 치료약과의 병용 또는 조합으로 이루어지는 의약 | |
CN107223125B (zh) | sGC刺激剂 | |
AU2021236532A1 (en) | Methods and compositions for treating aging-associated impairments using CCR3-inhibitors | |
JP2016540017A (ja) | sGC刺激物質 | |
US20230059381A1 (en) | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome | |
CN108430475B (zh) | 用于治疗慢性咳嗽的奥维匹坦 | |
KR20180125966A (ko) | 근위축성 측색 경화증 환자 아집단의 치료를 위한 마시티닙의 용도 | |
WO2014004676A1 (en) | Use of faah inhibitors as neuroprotective agents in the cns | |
BR112019020754A2 (pt) | métodos de prevenção ou tratamento de doenças oftalmológicas | |
CN112672742B (zh) | 纤维化治疗用医药组合物 | |
CN107073013A (zh) | 7‑氟‑8‑氯‑5H‑二苯并[b,e][1,4]二氮杂卓的衍生物及其用途 | |
US20110313153A1 (en) | 5-ht4 inhibitors for treating airway diseases, in particular asthma | |
CA3189152A1 (en) | Combination therapies with olig2 inhibitors | |
WO2020094592A1 (en) | Compounds for treating negative symptoms and cognitive impairments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200814 |
|
CF01 | Termination of patent right due to non-payment of annual fee |